# PeptideScanner evidence objects: Desmopressin

Every published version of the records placed with Desmopressin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/desmopressin.json. Selected public evidence only; not medical advice.

- Objects: 101
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00223717-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT00223717

> PeptideScanner retained ClinicalTrials.gov record NCT00223717 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-10-13, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct00223717-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00223717-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct00223717-desmopressin-v1
- Content SHA-256: `0609d7c6d7963d28d9e10113f805b3cff5c708bae0055c433aadb16207066353`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00223717 ([`ctg-observation-nct00223717-2017-10-13-bb6baa0a1303`](#source-ctg-observation-nct00223717-2017-10-13-bb6baa0a1303))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00223717 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-10-13, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct00223717-2017-10-13-bb6baa0a1303`](#source-ctg-observation-nct00223717-2017-10-13-bb6baa0a1303))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00223717 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-10-13, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct00223717-2017-10-13-bb6baa0a1303`](#source-ctg-observation-nct00223717-2017-10-13-bb6baa0a1303))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00223717-2017-10-13-bb6baa0a1303`](#source-ctg-observation-nct00223717-2017-10-13-bb6baa0a1303))

### Sources

<a id="source-ctg-observation-nct00223717-2017-10-13-bb6baa0a1303"></a>
- **ClinicalTrials.gov record NCT00223717 · retained source version 2017-10-13:bb6baa0a1303c4343cb16c9f897ba8178e276893e2fb9306d14d7181cdd62f22** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00223717) (`ctg-observation-nct00223717-2017-10-13-bb6baa0a1303`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00223717." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct00223717-desmopressin-v1 SHA-256: 0609d7c6d7963d28d9e10113f805b3cff5c708bae0055c433aadb16207066353.

---

<a id="clinicaltrials-gov-nct00230594-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT00230594

> PeptideScanner retained ClinicalTrials.gov record NCT00230594 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct00230594-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-05-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00230594-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct00230594-desmopressin-v1
- Content SHA-256: `d324ada601a2f4fe5ff0a31d7af2da958078f159187026d813f28a6d42360e17`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00230594 ([`ctg-observation-nct00230594-2011-05-19-2dbd8e810b74`](#source-ctg-observation-nct00230594-2011-05-19-2dbd8e810b74))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00230594 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct00230594-2011-05-19-2dbd8e810b74`](#source-ctg-observation-nct00230594-2011-05-19-2dbd8e810b74))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00230594 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct00230594-2011-05-19-2dbd8e810b74`](#source-ctg-observation-nct00230594-2011-05-19-2dbd8e810b74))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00230594-2011-05-19-2dbd8e810b74`](#source-ctg-observation-nct00230594-2011-05-19-2dbd8e810b74))

### Sources

<a id="source-ctg-observation-nct00230594-2011-05-19-2dbd8e810b74"></a>
- **ClinicalTrials.gov record NCT00230594 · retained source version 2011-05-19:2dbd8e810b74891e68526859881d6925b32bde5e7ff34a65d0c5fd0f4fc6da84** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00230594) (`ctg-observation-nct00230594-2011-05-19-2dbd8e810b74`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00230594." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct00230594-desmopressin-v1 SHA-256: d324ada601a2f4fe5ff0a31d7af2da958078f159187026d813f28a6d42360e17.

---

<a id="clinicaltrials-gov-nct00902265-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT00902265

> PeptideScanner retained ClinicalTrials.gov record NCT00902265 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct00902265-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-04-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00902265-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct00902265-desmopressin-v1
- Content SHA-256: `086a0d4f892fe5b2c1f8946bca22e787245bebfd1bbacaf3d30060d252f8ec6a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00902265 ([`ctg-observation-nct00902265-2011-04-19-bf16bc190c59`](#source-ctg-observation-nct00902265-2011-04-19-bf16bc190c59))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00902265 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct00902265-2011-04-19-bf16bc190c59`](#source-ctg-observation-nct00902265-2011-04-19-bf16bc190c59))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00902265 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct00902265-2011-04-19-bf16bc190c59`](#source-ctg-observation-nct00902265-2011-04-19-bf16bc190c59))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00902265-2011-04-19-bf16bc190c59`](#source-ctg-observation-nct00902265-2011-04-19-bf16bc190c59))

### Sources

<a id="source-ctg-observation-nct00902265-2011-04-19-bf16bc190c59"></a>
- **ClinicalTrials.gov record NCT00902265 · retained source version 2011-04-19:bf16bc190c59f877fa6269c837e5dbd39660d956c5ef3e2281d6e9b4660bc479** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00902265) (`ctg-observation-nct00902265-2011-04-19-bf16bc190c59`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00902265." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct00902265-desmopressin-v1 SHA-256: 086a0d4f892fe5b2c1f8946bca22e787245bebfd1bbacaf3d30060d252f8ec6a.

---

<a id="clinicaltrials-gov-nct00902655-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT00902655

> PeptideScanner retained ClinicalTrials.gov record NCT00902655 at 2026-11-16T01:33:21.554Z. Its registry update date was 2009-05-15, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct00902655-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-05-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00902655-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct00902655-desmopressin-v1
- Content SHA-256: `051912444b239589d1ef1e4d19f558a132841b44db00df16bc50b9f9daeff273`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00902655 ([`ctg-observation-nct00902655-2009-05-15-cb796c102f8b`](#source-ctg-observation-nct00902655-2009-05-15-cb796c102f8b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00902655 at 2026-11-16T01:33:21.554Z. Its registry update date was 2009-05-15, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct00902655-2009-05-15-cb796c102f8b`](#source-ctg-observation-nct00902655-2009-05-15-cb796c102f8b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00902655 at 2026-11-16T01:33:21.554Z. Its registry update date was 2009-05-15, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct00902655-2009-05-15-cb796c102f8b`](#source-ctg-observation-nct00902655-2009-05-15-cb796c102f8b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00902655-2009-05-15-cb796c102f8b`](#source-ctg-observation-nct00902655-2009-05-15-cb796c102f8b))

### Sources

<a id="source-ctg-observation-nct00902655-2009-05-15-cb796c102f8b"></a>
- **ClinicalTrials.gov record NCT00902655 · retained source version 2009-05-15:cb796c102f8b1323fd749dd401fd000c46d2d9c5b204d0235a599d65751f673a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00902655) (`ctg-observation-nct00902655-2009-05-15-cb796c102f8b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00902655." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct00902655-desmopressin-v1 SHA-256: 051912444b239589d1ef1e4d19f558a132841b44db00df16bc50b9f9daeff273.

---

<a id="clinicaltrials-gov-nct01078753-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01078753

> PeptideScanner retained ClinicalTrials.gov record NCT01078753 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01078753-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-11-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01078753-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01078753-desmopressin-v1
- Content SHA-256: `25fe7328990999a4c9e5cd700f6d65ea18c68750c3429e2d6d108e5d054a9dca`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01078753 ([`ctg-observation-nct01078753-2011-11-02-9cfb50f490c0`](#source-ctg-observation-nct01078753-2011-11-02-9cfb50f490c0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01078753 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01078753-2011-11-02-9cfb50f490c0`](#source-ctg-observation-nct01078753-2011-11-02-9cfb50f490c0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01078753 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01078753-2011-11-02-9cfb50f490c0`](#source-ctg-observation-nct01078753-2011-11-02-9cfb50f490c0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01078753-2011-11-02-9cfb50f490c0`](#source-ctg-observation-nct01078753-2011-11-02-9cfb50f490c0))

### Sources

<a id="source-ctg-observation-nct01078753-2011-11-02-9cfb50f490c0"></a>
- **ClinicalTrials.gov record NCT01078753 · retained source version 2011-11-02:9cfb50f490c0b44b0976854f6ccd6352200ded53e69fcdcfec266c9c795bd14c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01078753) (`ctg-observation-nct01078753-2011-11-02-9cfb50f490c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01078753." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01078753-desmopressin-v1 SHA-256: 25fe7328990999a4c9e5cd700f6d65ea18c68750c3429e2d6d108e5d054a9dca.

---

<a id="clinicaltrials-gov-nct01184859-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01184859

> PeptideScanner retained ClinicalTrials.gov record NCT01184859 at 2026-11-16T01:33:21.554Z. Its registry update date was 2012-05-25, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01184859-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-05-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01184859-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01184859-desmopressin-v1
- Content SHA-256: `515af128b1024ce8327519b762201b136cd380458ffc4bb8ee007bc7f6a26664`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01184859 ([`ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c`](#source-ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01184859 at 2026-11-16T01:33:21.554Z. Its registry update date was 2012-05-25, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c`](#source-ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01184859 at 2026-11-16T01:33:21.554Z. Its registry update date was 2012-05-25, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c`](#source-ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c`](#source-ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c))

### Sources

<a id="source-ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c"></a>
- **ClinicalTrials.gov record NCT01184859 · retained source version 2012-05-25:c3ff9d819c9ce9c81ab4b7f9cc1f690e28c523ffed058bc58e8c4741cd68872c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01184859) (`ctg-observation-nct01184859-2012-05-25-c3ff9d819c9c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01184859." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01184859-desmopressin-v1 SHA-256: 515af128b1024ce8327519b762201b136cd380458ffc4bb8ee007bc7f6a26664.

---

<a id="clinicaltrials-gov-nct01223937-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01223937

> PeptideScanner retained ClinicalTrials.gov record NCT01223937 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01223937-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-10-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01223937-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01223937-desmopressin-v1
- Content SHA-256: `a650166958b7ae28964b9f06d84e7567b1e5e31af6f2e6d4889a9c8c615dfbc4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01223937 ([`ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060`](#source-ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01223937 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060`](#source-ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01223937 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060`](#source-ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060`](#source-ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060))

### Sources

<a id="source-ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060"></a>
- **ClinicalTrials.gov record NCT01223937 · retained source version 2015-10-15:c9d6c8d5c060ce79a820cc99421a4ffb18c74120e4c906015802c4132a162350** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01223937) (`ctg-observation-nct01223937-2015-10-15-c9d6c8d5c060`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01223937." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01223937-desmopressin-v1 SHA-256: a650166958b7ae28964b9f06d84e7567b1e5e31af6f2e6d4889a9c8c615dfbc4.

---

<a id="clinicaltrials-gov-nct01262456-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01262456

> PeptideScanner retained ClinicalTrials.gov record NCT01262456 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01262456-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-10-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01262456-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01262456-desmopressin-v1
- Content SHA-256: `9478599c1023ae6bcf2febf33bbfadea6831aff09e69167245467cf8be48b45b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01262456 ([`ctg-observation-nct01262456-2015-10-15-7f4842eca9dd`](#source-ctg-observation-nct01262456-2015-10-15-7f4842eca9dd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01262456 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01262456-2015-10-15-7f4842eca9dd`](#source-ctg-observation-nct01262456-2015-10-15-7f4842eca9dd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01262456 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01262456-2015-10-15-7f4842eca9dd`](#source-ctg-observation-nct01262456-2015-10-15-7f4842eca9dd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01262456-2015-10-15-7f4842eca9dd`](#source-ctg-observation-nct01262456-2015-10-15-7f4842eca9dd))

### Sources

<a id="source-ctg-observation-nct01262456-2015-10-15-7f4842eca9dd"></a>
- **ClinicalTrials.gov record NCT01262456 · retained source version 2015-10-15:7f4842eca9dd2b4cebc77196ad0ef67f7777f1317cd4dcea56a0ee467571188c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01262456) (`ctg-observation-nct01262456-2015-10-15-7f4842eca9dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01262456." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01262456-desmopressin-v1 SHA-256: 9478599c1023ae6bcf2febf33bbfadea6831aff09e69167245467cf8be48b45b.

---

<a id="clinicaltrials-gov-nct01435083-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01435083

> PeptideScanner retained ClinicalTrials.gov record NCT01435083 at 2026-11-16T01:33:21.554Z. Its registry update date was 2014-12-05, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01435083-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-12-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01435083-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01435083-desmopressin-v1
- Content SHA-256: `cad83a4b1853bfc8e332d55984607df073ee505f8b81b1a036a4c7f24ec1fe85`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01435083 ([`ctg-observation-nct01435083-2014-12-05-276b5d5d6761`](#source-ctg-observation-nct01435083-2014-12-05-276b5d5d6761))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01435083 at 2026-11-16T01:33:21.554Z. Its registry update date was 2014-12-05, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01435083-2014-12-05-276b5d5d6761`](#source-ctg-observation-nct01435083-2014-12-05-276b5d5d6761))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01435083 at 2026-11-16T01:33:21.554Z. Its registry update date was 2014-12-05, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01435083-2014-12-05-276b5d5d6761`](#source-ctg-observation-nct01435083-2014-12-05-276b5d5d6761))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01435083-2014-12-05-276b5d5d6761`](#source-ctg-observation-nct01435083-2014-12-05-276b5d5d6761))

### Sources

<a id="source-ctg-observation-nct01435083-2014-12-05-276b5d5d6761"></a>
- **ClinicalTrials.gov record NCT01435083 · retained source version 2014-12-05:276b5d5d6761eff3e4e5f681a632b2d2633d0aae717dbe1dfb68e8e71e1c4a6a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01435083) (`ctg-observation-nct01435083-2014-12-05-276b5d5d6761`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01435083." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01435083-desmopressin-v1 SHA-256: cad83a4b1853bfc8e332d55984607df073ee505f8b81b1a036a4c7f24ec1fe85.

---

<a id="clinicaltrials-gov-nct01439997-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01439997

> PeptideScanner retained ClinicalTrials.gov record NCT01439997 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-12-15, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01439997-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-12-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01439997-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01439997-desmopressin-v1
- Content SHA-256: `1d35f72c580328fba7171ad2f3a10c4fd89601f4470f5446b5d0c60c5ec71a43`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01439997 ([`ctg-observation-nct01439997-2022-12-15-6f3447234da2`](#source-ctg-observation-nct01439997-2022-12-15-6f3447234da2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01439997 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-12-15, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01439997-2022-12-15-6f3447234da2`](#source-ctg-observation-nct01439997-2022-12-15-6f3447234da2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01439997 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-12-15, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01439997-2022-12-15-6f3447234da2`](#source-ctg-observation-nct01439997-2022-12-15-6f3447234da2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01439997-2022-12-15-6f3447234da2`](#source-ctg-observation-nct01439997-2022-12-15-6f3447234da2))

### Sources

<a id="source-ctg-observation-nct01439997-2022-12-15-6f3447234da2"></a>
- **ClinicalTrials.gov record NCT01439997 · retained source version 2022-12-15:6f3447234da2db32ac941294a5c02f4f4ad02521521a15ed1b7aa3c47c5e49bc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01439997) (`ctg-observation-nct01439997-2022-12-15-6f3447234da2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01439997." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01439997-desmopressin-v1 SHA-256: 1d35f72c580328fba7171ad2f3a10c4fd89601f4470f5446b5d0c60c5ec71a43.

---

<a id="clinicaltrials-gov-nct01552343-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01552343

> PeptideScanner retained ClinicalTrials.gov record NCT01552343 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-07-11, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01552343-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-07-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01552343-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01552343-desmopressin-v1
- Content SHA-256: `c2273b2f99842c7347e948bfc4317b0637de95a191cace1e6e7fc4560fa5d2c2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01552343 ([`ctg-observation-nct01552343-2017-07-11-ff80cb54cdff`](#source-ctg-observation-nct01552343-2017-07-11-ff80cb54cdff))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01552343 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-07-11, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01552343-2017-07-11-ff80cb54cdff`](#source-ctg-observation-nct01552343-2017-07-11-ff80cb54cdff))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01552343 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-07-11, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01552343-2017-07-11-ff80cb54cdff`](#source-ctg-observation-nct01552343-2017-07-11-ff80cb54cdff))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01552343-2017-07-11-ff80cb54cdff`](#source-ctg-observation-nct01552343-2017-07-11-ff80cb54cdff))

### Sources

<a id="source-ctg-observation-nct01552343-2017-07-11-ff80cb54cdff"></a>
- **ClinicalTrials.gov record NCT01552343 · retained source version 2017-07-11:ff80cb54cdffd0b9de457249181df775e0983a6b05ee1b39c17c1de9b7b8da2b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01552343) (`ctg-observation-nct01552343-2017-07-11-ff80cb54cdff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01552343." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01552343-desmopressin-v1 SHA-256: c2273b2f99842c7347e948bfc4317b0637de95a191cace1e6e7fc4560fa5d2c2.

---

<a id="clinicaltrials-gov-nct01606072-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01606072

> PeptideScanner retained ClinicalTrials.gov record NCT01606072 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-08-28, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01606072-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01606072-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01606072-desmopressin-v1
- Content SHA-256: `c18498aae6cbd64c0be7e392c3c0404f7ffbe9bae073900616681e8516ac00e6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01606072 ([`ctg-observation-nct01606072-2015-08-28-6ff72be9c761`](#source-ctg-observation-nct01606072-2015-08-28-6ff72be9c761))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01606072 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-08-28, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01606072-2015-08-28-6ff72be9c761`](#source-ctg-observation-nct01606072-2015-08-28-6ff72be9c761))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01606072 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-08-28, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01606072-2015-08-28-6ff72be9c761`](#source-ctg-observation-nct01606072-2015-08-28-6ff72be9c761))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01606072-2015-08-28-6ff72be9c761`](#source-ctg-observation-nct01606072-2015-08-28-6ff72be9c761))

### Sources

<a id="source-ctg-observation-nct01606072-2015-08-28-6ff72be9c761"></a>
- **ClinicalTrials.gov record NCT01606072 · retained source version 2015-08-28:6ff72be9c7610b7e308024d6b041099e40023294e2573339c9e8b8686d0ce64d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01606072) (`ctg-observation-nct01606072-2015-08-28-6ff72be9c761`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01606072." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01606072-desmopressin-v1 SHA-256: c18498aae6cbd64c0be7e392c3c0404f7ffbe9bae073900616681e8516ac00e6.

---

<a id="clinicaltrials-gov-nct01994330-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT01994330

> PeptideScanner retained ClinicalTrials.gov record NCT01994330 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct01994330-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01994330-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01994330-desmopressin-v1
- Content SHA-256: `320af02f489a5d4cad3d840fea77fa6cef082c4b08f59becbc5f508f2deb5b93`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01994330 ([`ctg-observation-nct01994330-2017-04-05-7b8187f0de70`](#source-ctg-observation-nct01994330-2017-04-05-7b8187f0de70))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01994330 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01994330-2017-04-05-7b8187f0de70`](#source-ctg-observation-nct01994330-2017-04-05-7b8187f0de70))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01994330 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct01994330-2017-04-05-7b8187f0de70`](#source-ctg-observation-nct01994330-2017-04-05-7b8187f0de70))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01994330-2017-04-05-7b8187f0de70`](#source-ctg-observation-nct01994330-2017-04-05-7b8187f0de70))

### Sources

<a id="source-ctg-observation-nct01994330-2017-04-05-7b8187f0de70"></a>
- **ClinicalTrials.gov record NCT01994330 · retained source version 2017-04-05:7b8187f0de70901f919ade8e92db20803cb1d1a0ee9648222ce897a4164232fe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01994330) (`ctg-observation-nct01994330-2017-04-05-7b8187f0de70`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01994330." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct01994330-desmopressin-v1 SHA-256: 320af02f489a5d4cad3d840fea77fa6cef082c4b08f59becbc5f508f2deb5b93.

---

<a id="clinicaltrials-gov-nct02125188-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT02125188

> PeptideScanner retained ClinicalTrials.gov record NCT02125188 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct02125188-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-06-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02125188-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02125188-desmopressin-v1
- Content SHA-256: `15177ddd6190f86b7b64c0c656c1ea64af3ac83680de5ce442b40a7b5dde6b67`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02125188 ([`ctg-observation-nct02125188-2017-06-06-abc1fa012959`](#source-ctg-observation-nct02125188-2017-06-06-abc1fa012959))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02125188 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02125188-2017-06-06-abc1fa012959`](#source-ctg-observation-nct02125188-2017-06-06-abc1fa012959))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02125188 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02125188-2017-06-06-abc1fa012959`](#source-ctg-observation-nct02125188-2017-06-06-abc1fa012959))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02125188-2017-06-06-abc1fa012959`](#source-ctg-observation-nct02125188-2017-06-06-abc1fa012959))

### Sources

<a id="source-ctg-observation-nct02125188-2017-06-06-abc1fa012959"></a>
- **ClinicalTrials.gov record NCT02125188 · retained source version 2017-06-06:abc1fa012959268efd5f42b4f301482c7d6ddf6905c299f0488aad5d3acdff10** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02125188) (`ctg-observation-nct02125188-2017-06-06-abc1fa012959`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02125188." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02125188-desmopressin-v1 SHA-256: 15177ddd6190f86b7b64c0c656c1ea64af3ac83680de5ce442b40a7b5dde6b67.

---

<a id="clinicaltrials-gov-nct02506023-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT02506023

> PeptideScanner retained ClinicalTrials.gov record NCT02506023 at 2026-11-16T01:33:21.554Z. Its registry update date was 2018-07-16, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct02506023-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-07-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02506023-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02506023-desmopressin-v1
- Content SHA-256: `2ad42dff03476f879bea1244b74e83bb69032d9dbf59c26bf3e7a2ebccf3b74b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02506023 ([`ctg-observation-nct02506023-2018-07-16-0fe642b93542`](#source-ctg-observation-nct02506023-2018-07-16-0fe642b93542))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02506023 at 2026-11-16T01:33:21.554Z. Its registry update date was 2018-07-16, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02506023-2018-07-16-0fe642b93542`](#source-ctg-observation-nct02506023-2018-07-16-0fe642b93542))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02506023 at 2026-11-16T01:33:21.554Z. Its registry update date was 2018-07-16, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02506023-2018-07-16-0fe642b93542`](#source-ctg-observation-nct02506023-2018-07-16-0fe642b93542))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02506023-2018-07-16-0fe642b93542`](#source-ctg-observation-nct02506023-2018-07-16-0fe642b93542))

### Sources

<a id="source-ctg-observation-nct02506023-2018-07-16-0fe642b93542"></a>
- **ClinicalTrials.gov record NCT02506023 · retained source version 2018-07-16:0fe642b935424650bf05d8e42eccd9d28b78832e9ec2ee9d10515a148176c7df** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02506023) (`ctg-observation-nct02506023-2018-07-16-0fe642b93542`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02506023." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02506023-desmopressin-v1 SHA-256: 2ad42dff03476f879bea1244b74e83bb69032d9dbf59c26bf3e7a2ebccf3b74b.

---

<a id="clinicaltrials-gov-nct02584231-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT02584231

> PeptideScanner retained ClinicalTrials.gov record NCT02584231 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-02-06, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct02584231-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-02-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02584231-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02584231-desmopressin-v1
- Content SHA-256: `3a19572a5ba0869870d443df14184117ae3012893334a7663896ef70be38da22`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02584231 ([`ctg-observation-nct02584231-2019-02-06-e1a274767e56`](#source-ctg-observation-nct02584231-2019-02-06-e1a274767e56))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02584231 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-02-06, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02584231-2019-02-06-e1a274767e56`](#source-ctg-observation-nct02584231-2019-02-06-e1a274767e56))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02584231 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-02-06, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02584231-2019-02-06-e1a274767e56`](#source-ctg-observation-nct02584231-2019-02-06-e1a274767e56))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02584231-2019-02-06-e1a274767e56`](#source-ctg-observation-nct02584231-2019-02-06-e1a274767e56))

### Sources

<a id="source-ctg-observation-nct02584231-2019-02-06-e1a274767e56"></a>
- **ClinicalTrials.gov record NCT02584231 · retained source version 2019-02-06:e1a274767e569619cfb6e541a5594d84f59fceb0f792c83b731c108cd4d48ebe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02584231) (`ctg-observation-nct02584231-2019-02-06-e1a274767e56`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02584231." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02584231-desmopressin-v1 SHA-256: 3a19572a5ba0869870d443df14184117ae3012893334a7663896ef70be38da22.

---

<a id="clinicaltrials-gov-nct02904759-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT02904759

> PeptideScanner retained ClinicalTrials.gov record NCT02904759 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct02904759-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-09-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02904759-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02904759-desmopressin-v1
- Content SHA-256: `fe5c93c1c0e0e566020cb0d00dedbe772e091e20ae8b92e6e4ff242e9c6fbf00`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02904759 ([`ctg-observation-nct02904759-2019-09-11-408de6483f02`](#source-ctg-observation-nct02904759-2019-09-11-408de6483f02))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02904759 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02904759-2019-09-11-408de6483f02`](#source-ctg-observation-nct02904759-2019-09-11-408de6483f02))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02904759 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02904759-2019-09-11-408de6483f02`](#source-ctg-observation-nct02904759-2019-09-11-408de6483f02))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02904759-2019-09-11-408de6483f02`](#source-ctg-observation-nct02904759-2019-09-11-408de6483f02))

### Sources

<a id="source-ctg-observation-nct02904759-2019-09-11-408de6483f02"></a>
- **ClinicalTrials.gov record NCT02904759 · retained source version 2019-09-11:408de6483f02a80fcde5b2e0e4ac9919b2d1d54981f33bfb99a5b1f9f4b2377d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02904759) (`ctg-observation-nct02904759-2019-09-11-408de6483f02`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02904759." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02904759-desmopressin-v1 SHA-256: fe5c93c1c0e0e566020cb0d00dedbe772e091e20ae8b92e6e4ff242e9c6fbf00.

---

<a id="clinicaltrials-gov-nct02905682-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT02905682

> PeptideScanner retained ClinicalTrials.gov record NCT02905682 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct02905682-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-09-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02905682-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02905682-desmopressin-v1
- Content SHA-256: `3993084db95e10b234b934346ad607ddab517bbd20ff1c9ef9f7e69ee18c6009`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02905682 ([`ctg-observation-nct02905682-2019-09-11-c00721275eb9`](#source-ctg-observation-nct02905682-2019-09-11-c00721275eb9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02905682 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02905682-2019-09-11-c00721275eb9`](#source-ctg-observation-nct02905682-2019-09-11-c00721275eb9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02905682 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct02905682-2019-09-11-c00721275eb9`](#source-ctg-observation-nct02905682-2019-09-11-c00721275eb9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02905682-2019-09-11-c00721275eb9`](#source-ctg-observation-nct02905682-2019-09-11-c00721275eb9))

### Sources

<a id="source-ctg-observation-nct02905682-2019-09-11-c00721275eb9"></a>
- **ClinicalTrials.gov record NCT02905682 · retained source version 2019-09-11:c00721275eb9d5e712a402e418fb1789d2033e8c2f4feb8dd6853849b5995383** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02905682) (`ctg-observation-nct02905682-2019-09-11-c00721275eb9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02905682." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct02905682-desmopressin-v1 SHA-256: 3993084db95e10b234b934346ad607ddab517bbd20ff1c9ef9f7e69ee18c6009.

---

<a id="clinicaltrials-gov-nct03201419-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT03201419

> PeptideScanner retained ClinicalTrials.gov record NCT03201419 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-03-02, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct03201419-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-03-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03201419-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct03201419-desmopressin-v1
- Content SHA-256: `5c5c528f6197ff90f7fe2bc2c1cbec277d636cfc2f28a66abdb55765ecb93eb0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03201419 ([`ctg-observation-nct03201419-2022-03-02-2732b80880f8`](#source-ctg-observation-nct03201419-2022-03-02-2732b80880f8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03201419 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-03-02, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct03201419-2022-03-02-2732b80880f8`](#source-ctg-observation-nct03201419-2022-03-02-2732b80880f8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03201419 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-03-02, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct03201419-2022-03-02-2732b80880f8`](#source-ctg-observation-nct03201419-2022-03-02-2732b80880f8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03201419-2022-03-02-2732b80880f8`](#source-ctg-observation-nct03201419-2022-03-02-2732b80880f8))

### Sources

<a id="source-ctg-observation-nct03201419-2022-03-02-2732b80880f8"></a>
- **ClinicalTrials.gov record NCT03201419 · retained source version 2022-03-02:2732b80880f8b430c7dfdf5a48bdf931c05764db89f3ecf1e85401635b58cdc8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03201419) (`ctg-observation-nct03201419-2022-03-02-2732b80880f8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03201419." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct03201419-desmopressin-v1 SHA-256: 5c5c528f6197ff90f7fe2bc2c1cbec277d636cfc2f28a66abdb55765ecb93eb0.

---

<a id="clinicaltrials-gov-nct03389412-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT03389412

> PeptideScanner retained ClinicalTrials.gov record NCT03389412 at 2026-11-16T01:33:21.554Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct03389412-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-08-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03389412-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct03389412-desmopressin-v1
- Content SHA-256: `0b913968f440052feea73463d2cbf01fb76276220054bcaa893718050c99686f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03389412 ([`ctg-observation-nct03389412-2023-08-02-efb644dfe6c9`](#source-ctg-observation-nct03389412-2023-08-02-efb644dfe6c9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03389412 at 2026-11-16T01:33:21.554Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct03389412-2023-08-02-efb644dfe6c9`](#source-ctg-observation-nct03389412-2023-08-02-efb644dfe6c9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03389412 at 2026-11-16T01:33:21.554Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct03389412-2023-08-02-efb644dfe6c9`](#source-ctg-observation-nct03389412-2023-08-02-efb644dfe6c9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03389412-2023-08-02-efb644dfe6c9`](#source-ctg-observation-nct03389412-2023-08-02-efb644dfe6c9))

### Sources

<a id="source-ctg-observation-nct03389412-2023-08-02-efb644dfe6c9"></a>
- **ClinicalTrials.gov record NCT03389412 · retained source version 2023-08-02:efb644dfe6c950bb4378248dc23d910fddcbcebbe94cdf55cf038e127cded328** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03389412) (`ctg-observation-nct03389412-2023-08-02-efb644dfe6c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03389412." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct03389412-desmopressin-v1 SHA-256: 0b913968f440052feea73463d2cbf01fb76276220054bcaa893718050c99686f.

---

<a id="clinicaltrials-gov-nct04103034-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT04103034

> PeptideScanner retained ClinicalTrials.gov record NCT04103034 at 2026-11-16T01:33:21.554Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct04103034-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-03-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04103034-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct04103034-desmopressin-v1
- Content SHA-256: `27d66812ba075afd676f08e6c729d62379ee3503374e6b7e07939cd67a7d2dd5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04103034 ([`ctg-observation-nct04103034-2024-03-18-86add58eb12a`](#source-ctg-observation-nct04103034-2024-03-18-86add58eb12a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04103034 at 2026-11-16T01:33:21.554Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct04103034-2024-03-18-86add58eb12a`](#source-ctg-observation-nct04103034-2024-03-18-86add58eb12a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04103034 at 2026-11-16T01:33:21.554Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct04103034-2024-03-18-86add58eb12a`](#source-ctg-observation-nct04103034-2024-03-18-86add58eb12a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04103034-2024-03-18-86add58eb12a`](#source-ctg-observation-nct04103034-2024-03-18-86add58eb12a))

### Sources

<a id="source-ctg-observation-nct04103034-2024-03-18-86add58eb12a"></a>
- **ClinicalTrials.gov record NCT04103034 · retained source version 2024-03-18:86add58eb12ad2a8b02b70a2f772b01c9107d4d91eae70002be2c22766e2ab32** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04103034) (`ctg-observation-nct04103034-2024-03-18-86add58eb12a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04103034." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct04103034-desmopressin-v1 SHA-256: 27d66812ba075afd676f08e6c729d62379ee3503374e6b7e07939cd67a7d2dd5.

---

<a id="clinicaltrials-gov-nct05467033-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT05467033

> PeptideScanner retained ClinicalTrials.gov record NCT05467033 at 2026-11-16T01:33:21.554Z. Its registry update date was 2025-05-08, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct05467033-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05467033-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct05467033-desmopressin-v1
- Content SHA-256: `d925ce6c15540004583a4dfffc3fc18635d9ea26741e6257227afdfa71a28093`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05467033 ([`ctg-observation-nct05467033-2025-05-08-2d92b52ea132`](#source-ctg-observation-nct05467033-2025-05-08-2d92b52ea132))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05467033 at 2026-11-16T01:33:21.554Z. Its registry update date was 2025-05-08, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct05467033-2025-05-08-2d92b52ea132`](#source-ctg-observation-nct05467033-2025-05-08-2d92b52ea132))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05467033 at 2026-11-16T01:33:21.554Z. Its registry update date was 2025-05-08, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct05467033-2025-05-08-2d92b52ea132`](#source-ctg-observation-nct05467033-2025-05-08-2d92b52ea132))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05467033-2025-05-08-2d92b52ea132`](#source-ctg-observation-nct05467033-2025-05-08-2d92b52ea132))

### Sources

<a id="source-ctg-observation-nct05467033-2025-05-08-2d92b52ea132"></a>
- **ClinicalTrials.gov record NCT05467033 · retained source version 2025-05-08:2d92b52ea13217db65b1639ce120b501446de520efc97b4c1ee0f1cecf591e19** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05467033) (`ctg-observation-nct05467033-2025-05-08-2d92b52ea132`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05467033." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct05467033-desmopressin-v1 SHA-256: d925ce6c15540004583a4dfffc3fc18635d9ea26741e6257227afdfa71a28093.

---

<a id="clinicaltrials-gov-nct06020495-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT06020495

> PeptideScanner retained ClinicalTrials.gov record NCT06020495 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct06020495-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06020495-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct06020495-desmopressin-v1
- Content SHA-256: `8eebff981258d86efecea9926956115058b62c54b79b61178fa20de35c62017d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06020495 ([`ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8`](#source-ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06020495 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8`](#source-ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06020495 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8`](#source-ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8`](#source-ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8))

### Sources

<a id="source-ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8"></a>
- **ClinicalTrials.gov record NCT06020495 · retained source version 2026-10-30:9fb3c53ae1b8a5e92d12b71dfd42d7d2438d0c7633bb7cf029eea75d9a7ca23b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06020495) (`ctg-observation-nct06020495-2026-10-30-9fb3c53ae1b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06020495." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct06020495-desmopressin-v1 SHA-256: 8eebff981258d86efecea9926956115058b62c54b79b61178fa20de35c62017d.

---

<a id="clinicaltrials-gov-nct06337838-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT06337838

> PeptideScanner retained ClinicalTrials.gov record NCT06337838 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct06337838-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06337838-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct06337838-desmopressin-v1
- Content SHA-256: `7f59897eaa7535f8bb9006e25d5aa2644b6e0470c017926c0b4706ca02d109ef`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06337838 ([`ctg-observation-nct06337838-2026-05-22-6c3e4b143f27`](#source-ctg-observation-nct06337838-2026-05-22-6c3e4b143f27))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06337838 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct06337838-2026-05-22-6c3e4b143f27`](#source-ctg-observation-nct06337838-2026-05-22-6c3e4b143f27))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06337838 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct06337838-2026-05-22-6c3e4b143f27`](#source-ctg-observation-nct06337838-2026-05-22-6c3e4b143f27))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06337838-2026-05-22-6c3e4b143f27`](#source-ctg-observation-nct06337838-2026-05-22-6c3e4b143f27))

### Sources

<a id="source-ctg-observation-nct06337838-2026-05-22-6c3e4b143f27"></a>
- **ClinicalTrials.gov record NCT06337838 · retained source version 2026-05-22:6c3e4b143f27bd5109df3cc188f6a70d0d091cc5b1118afd1b625216766ae132** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06337838) (`ctg-observation-nct06337838-2026-05-22-6c3e4b143f27`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06337838." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct06337838-desmopressin-v1 SHA-256: 7f59897eaa7535f8bb9006e25d5aa2644b6e0470c017926c0b4706ca02d109ef.

---

<a id="clinicaltrials-gov-nct06635629-desmopressin-v1"></a>

## ClinicalTrials.gov record NCT06635629

> PeptideScanner retained ClinicalTrials.gov record NCT06635629 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was desmopressin.

- Evidence object: `story:clinicaltrials-gov-nct06635629-desmopressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06635629-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct06635629-desmopressin-v1
- Content SHA-256: `837842d9f902de5a37a38a52f6565ec064cd0f383b0c1bdfdc44de2a04387da1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06635629 ([`ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9`](#source-ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06635629 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9`](#source-ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06635629 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was desmopressin. ([`ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9`](#source-ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9`](#source-ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9))

### Sources

<a id="source-ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9"></a>
- **ClinicalTrials.gov record NCT06635629 · retained source version 2026-08-31:60c6d9aebfd96e63f9e1fa9f31b4f48d2eb1880bae29c8016aca6ada61f85761** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06635629) (`ctg-observation-nct06635629-2026-08-31-60c6d9aebfd9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06635629." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#clinicaltrials-gov-nct06635629-desmopressin-v1 SHA-256: 837842d9f902de5a37a38a52f6565ec064cd0f383b0c1bdfdc44de2a04387da1.

---

<a id="fda-drugs-anda074574-v1"></a>

## Drugs@FDA application ANDA074574

> The official Drugs@FDA dataset lists original submission 1 for ANDA 074574 with status AP dated 2000-02-18, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda074574:v1`
- Evidence domain: Regulatory
- Date in source: 2000-02-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda074574/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda074574-v1
- Content SHA-256: `baed8a1d4cddd923567c6290e64cac7c5c07a1bcef762859c00e426e503d9df6`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA074574 ([`fda-drugs-anda074574-2000-02-18-2dd01343503b`](#source-fda-drugs-anda074574-2000-02-18-2dd01343503b))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 074574 with status AP dated 2000-02-18, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda074574-2000-02-18-2dd01343503b`](#source-fda-drugs-anda074574-2000-02-18-2dd01343503b))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 074574 with status AP dated 2000-02-18, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda074574-2000-02-18-2dd01343503b`](#source-fda-drugs-anda074574-2000-02-18-2dd01343503b))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda074574-2000-02-18-2dd01343503b`](#source-fda-drugs-anda074574-2000-02-18-2dd01343503b))

### Sources

<a id="source-fda-drugs-anda074574-2000-02-18-2dd01343503b"></a>
- **Drugs@FDA application ANDA074574 · original submission status AP · 2000-02-18 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA074574%22&limit=1) (`fda-drugs-anda074574-2000-02-18-2dd01343503b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA074574." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda074574-v1 SHA-256: baed8a1d4cddd923567c6290e64cac7c5c07a1bcef762859c00e426e503d9df6.

---

<a id="fda-drugs-anda074575-v1"></a>

## Drugs@FDA application ANDA074575

> The official Drugs@FDA dataset lists original submission 1 for ANDA 074575 with status AP dated 2000-02-18, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda074575:v1`
- Evidence domain: Regulatory
- Date in source: 2000-02-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda074575/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda074575-v1
- Content SHA-256: `4de0e9098026d5cd542fe88657e00396fb9052caa03d02723aecb456470df7ca`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA074575 ([`fda-drugs-anda074575-2000-02-18-628ad54ea6f8`](#source-fda-drugs-anda074575-2000-02-18-628ad54ea6f8))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 074575 with status AP dated 2000-02-18, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda074575-2000-02-18-628ad54ea6f8`](#source-fda-drugs-anda074575-2000-02-18-628ad54ea6f8))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 074575 with status AP dated 2000-02-18, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda074575-2000-02-18-628ad54ea6f8`](#source-fda-drugs-anda074575-2000-02-18-628ad54ea6f8))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda074575-2000-02-18-628ad54ea6f8`](#source-fda-drugs-anda074575-2000-02-18-628ad54ea6f8))

### Sources

<a id="source-fda-drugs-anda074575-2000-02-18-628ad54ea6f8"></a>
- **Drugs@FDA application ANDA074575 · original submission status AP · 2000-02-18 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA074575%22&limit=1) (`fda-drugs-anda074575-2000-02-18-628ad54ea6f8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA074575." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda074575-v1 SHA-256: 4de0e9098026d5cd542fe88657e00396fb9052caa03d02723aecb456470df7ca.

---

<a id="fda-drugs-anda074830-v1"></a>

## Drugs@FDA application ANDA074830

> The official Drugs@FDA dataset lists original submission 1 for ANDA 074830 with status AP dated 1999-01-25, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda074830:v1`
- Evidence domain: Regulatory
- Date in source: 1999-01-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda074830/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda074830-v1
- Content SHA-256: `3883fd50afa5c6972724a736cc0f1c6d5f1753bb753ab9cac1ae97c09a0cb291`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA074830 ([`fda-drugs-anda074830-1999-01-25-d04422aa61ad`](#source-fda-drugs-anda074830-1999-01-25-d04422aa61ad))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 074830 with status AP dated 1999-01-25, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda074830-1999-01-25-d04422aa61ad`](#source-fda-drugs-anda074830-1999-01-25-d04422aa61ad))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 074830 with status AP dated 1999-01-25, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda074830-1999-01-25-d04422aa61ad`](#source-fda-drugs-anda074830-1999-01-25-d04422aa61ad))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda074830-1999-01-25-d04422aa61ad`](#source-fda-drugs-anda074830-1999-01-25-d04422aa61ad))

### Sources

<a id="source-fda-drugs-anda074830-1999-01-25-d04422aa61ad"></a>
- **Drugs@FDA application ANDA074830 · original submission status AP · 1999-01-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA074830%22&limit=1) (`fda-drugs-anda074830-1999-01-25-d04422aa61ad`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA074830." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda074830-v1 SHA-256: 3883fd50afa5c6972724a736cc0f1c6d5f1753bb753ab9cac1ae97c09a0cb291.

---

<a id="fda-drugs-anda074888-v1"></a>

## Drugs@FDA application ANDA074888

> The official Drugs@FDA dataset lists original submission 1 for ANDA 074888 with status AP dated 1997-10-15, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda074888:v1`
- Evidence domain: Regulatory
- Date in source: 1997-10-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda074888/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda074888-v1
- Content SHA-256: `3f9b6f7548e4b288a59e5c4c81fac6db965ec05f96673e0730157eb9b1c3756c`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA074888 ([`fda-drugs-anda074888-1997-10-15-864f35ad954e`](#source-fda-drugs-anda074888-1997-10-15-864f35ad954e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 074888 with status AP dated 1997-10-15, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda074888-1997-10-15-864f35ad954e`](#source-fda-drugs-anda074888-1997-10-15-864f35ad954e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 074888 with status AP dated 1997-10-15, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda074888-1997-10-15-864f35ad954e`](#source-fda-drugs-anda074888-1997-10-15-864f35ad954e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda074888-1997-10-15-864f35ad954e`](#source-fda-drugs-anda074888-1997-10-15-864f35ad954e))

### Sources

<a id="source-fda-drugs-anda074888-1997-10-15-864f35ad954e"></a>
- **Drugs@FDA application ANDA074888 · original submission status AP · 1997-10-15 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA074888%22&limit=1) (`fda-drugs-anda074888-1997-10-15-864f35ad954e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA074888." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda074888-v1 SHA-256: 3f9b6f7548e4b288a59e5c4c81fac6db965ec05f96673e0730157eb9b1c3756c.

---

<a id="fda-drugs-anda075220-v1"></a>

## Drugs@FDA application ANDA075220

> The official Drugs@FDA dataset lists original submission 1 for ANDA 075220 with status AP dated 2000-08-28, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda075220:v1`
- Evidence domain: Regulatory
- Date in source: 2000-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda075220/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda075220-v1
- Content SHA-256: `df918c1f9f7025751ea0655d684015d3d4e6885df9de316f06617a485ce5c50e`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA075220 ([`fda-drugs-anda075220-2000-08-28-58f8879bbee3`](#source-fda-drugs-anda075220-2000-08-28-58f8879bbee3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 075220 with status AP dated 2000-08-28, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda075220-2000-08-28-58f8879bbee3`](#source-fda-drugs-anda075220-2000-08-28-58f8879bbee3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 075220 with status AP dated 2000-08-28, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda075220-2000-08-28-58f8879bbee3`](#source-fda-drugs-anda075220-2000-08-28-58f8879bbee3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda075220-2000-08-28-58f8879bbee3`](#source-fda-drugs-anda075220-2000-08-28-58f8879bbee3))

### Sources

<a id="source-fda-drugs-anda075220-2000-08-28-58f8879bbee3"></a>
- **Drugs@FDA application ANDA075220 · original submission status AP · 2000-08-28 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA075220%22&limit=1) (`fda-drugs-anda075220-2000-08-28-58f8879bbee3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA075220." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda075220-v1 SHA-256: df918c1f9f7025751ea0655d684015d3d4e6885df9de316f06617a485ce5c50e.

---

<a id="fda-drugs-anda076470-v1"></a>

## Drugs@FDA application ANDA076470

> The official Drugs@FDA dataset lists original submission 1 for ANDA 076470 with status AP dated 2005-07-01, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda076470:v1`
- Evidence domain: Regulatory
- Date in source: 2005-07-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda076470/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda076470-v1
- Content SHA-256: `0b4cea56845c8b8e4096e988b9873ea05317b8743bcf292d90e789d09652ab0c`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA076470 ([`fda-drugs-anda076470-2005-07-01-3a14d75e18b5`](#source-fda-drugs-anda076470-2005-07-01-3a14d75e18b5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 076470 with status AP dated 2005-07-01, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda076470-2005-07-01-3a14d75e18b5`](#source-fda-drugs-anda076470-2005-07-01-3a14d75e18b5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 076470 with status AP dated 2005-07-01, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda076470-2005-07-01-3a14d75e18b5`](#source-fda-drugs-anda076470-2005-07-01-3a14d75e18b5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda076470-2005-07-01-3a14d75e18b5`](#source-fda-drugs-anda076470-2005-07-01-3a14d75e18b5))

### Sources

<a id="source-fda-drugs-anda076470-2005-07-01-3a14d75e18b5"></a>
- **Drugs@FDA application ANDA076470 · original submission status AP · 2005-07-01 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA076470%22&limit=1) (`fda-drugs-anda076470-2005-07-01-3a14d75e18b5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA076470." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda076470-v1 SHA-256: 0b4cea56845c8b8e4096e988b9873ea05317b8743bcf292d90e789d09652ab0c.

---

<a id="fda-drugs-anda076703-v1"></a>

## Drugs@FDA application ANDA076703

> The official Drugs@FDA dataset lists original submission 1 for ANDA 076703 with status AP dated 2005-01-27, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda076703:v1`
- Evidence domain: Regulatory
- Date in source: 2005-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda076703/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda076703-v1
- Content SHA-256: `52e652b4aee4e57fd7bc9b1070c73702bb1fc6552ca353847100cbc9bbe3ae75`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA076703 ([`fda-drugs-anda076703-2005-01-27-ed10d366ef5c`](#source-fda-drugs-anda076703-2005-01-27-ed10d366ef5c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 076703 with status AP dated 2005-01-27, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda076703-2005-01-27-ed10d366ef5c`](#source-fda-drugs-anda076703-2005-01-27-ed10d366ef5c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 076703 with status AP dated 2005-01-27, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda076703-2005-01-27-ed10d366ef5c`](#source-fda-drugs-anda076703-2005-01-27-ed10d366ef5c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda076703-2005-01-27-ed10d366ef5c`](#source-fda-drugs-anda076703-2005-01-27-ed10d366ef5c))

### Sources

<a id="source-fda-drugs-anda076703-2005-01-27-ed10d366ef5c"></a>
- **Drugs@FDA application ANDA076703 · original submission status AP · 2005-01-27 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA076703%22&limit=1) (`fda-drugs-anda076703-2005-01-27-ed10d366ef5c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA076703." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda076703-v1 SHA-256: 52e652b4aee4e57fd7bc9b1070c73702bb1fc6552ca353847100cbc9bbe3ae75.

---

<a id="fda-drugs-anda077122-v1"></a>

## Drugs@FDA application ANDA077122

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077122 with status AP dated 2006-01-25, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077122:v1`
- Evidence domain: Regulatory
- Date in source: 2006-01-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077122/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda077122-v1
- Content SHA-256: `10d32536837f0fbaab609a5f87e9e575d0d54b2de8fbd2082433f8e4c41e4d69`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077122 ([`fda-drugs-anda077122-2006-01-25-c693410c831a`](#source-fda-drugs-anda077122-2006-01-25-c693410c831a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077122 with status AP dated 2006-01-25, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda077122-2006-01-25-c693410c831a`](#source-fda-drugs-anda077122-2006-01-25-c693410c831a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077122 with status AP dated 2006-01-25, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda077122-2006-01-25-c693410c831a`](#source-fda-drugs-anda077122-2006-01-25-c693410c831a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077122-2006-01-25-c693410c831a`](#source-fda-drugs-anda077122-2006-01-25-c693410c831a))

### Sources

<a id="source-fda-drugs-anda077122-2006-01-25-c693410c831a"></a>
- **Drugs@FDA application ANDA077122 · original submission status AP · 2006-01-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077122%22&limit=1) (`fda-drugs-anda077122-2006-01-25-c693410c831a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077122." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda077122-v1 SHA-256: 10d32536837f0fbaab609a5f87e9e575d0d54b2de8fbd2082433f8e4c41e4d69.

---

<a id="fda-drugs-anda077212-v1"></a>

## Drugs@FDA application ANDA077212

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077212 with status AP dated 2012-04-12, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077212:v1`
- Evidence domain: Regulatory
- Date in source: 2012-04-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077212/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda077212-v1
- Content SHA-256: `a2d8c54880918207fc2771ab8707adfabf4e69ea193de0eff6a49f1829e95ba5`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077212 ([`fda-drugs-anda077212-2012-04-12-fc125cc53e82`](#source-fda-drugs-anda077212-2012-04-12-fc125cc53e82))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077212 with status AP dated 2012-04-12, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda077212-2012-04-12-fc125cc53e82`](#source-fda-drugs-anda077212-2012-04-12-fc125cc53e82))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077212 with status AP dated 2012-04-12, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda077212-2012-04-12-fc125cc53e82`](#source-fda-drugs-anda077212-2012-04-12-fc125cc53e82))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077212-2012-04-12-fc125cc53e82`](#source-fda-drugs-anda077212-2012-04-12-fc125cc53e82))

### Sources

<a id="source-fda-drugs-anda077212-2012-04-12-fc125cc53e82"></a>
- **Drugs@FDA application ANDA077212 · original submission status AP · 2012-04-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077212%22&limit=1) (`fda-drugs-anda077212-2012-04-12-fc125cc53e82`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077212." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda077212-v1 SHA-256: a2d8c54880918207fc2771ab8707adfabf4e69ea193de0eff6a49f1829e95ba5.

---

<a id="fda-drugs-anda077414-v1"></a>

## Drugs@FDA application ANDA077414

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077414 with status AP dated 2006-03-07, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077414:v1`
- Evidence domain: Regulatory
- Date in source: 2006-03-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077414/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda077414-v1
- Content SHA-256: `74642911f374b2cd640a4fe13271a5e8e5e42c646a2971c123464304e64695d5`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077414 ([`fda-drugs-anda077414-2006-03-07-fb0f45c75d7f`](#source-fda-drugs-anda077414-2006-03-07-fb0f45c75d7f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077414 with status AP dated 2006-03-07, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda077414-2006-03-07-fb0f45c75d7f`](#source-fda-drugs-anda077414-2006-03-07-fb0f45c75d7f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077414 with status AP dated 2006-03-07, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda077414-2006-03-07-fb0f45c75d7f`](#source-fda-drugs-anda077414-2006-03-07-fb0f45c75d7f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077414-2006-03-07-fb0f45c75d7f`](#source-fda-drugs-anda077414-2006-03-07-fb0f45c75d7f))

### Sources

<a id="source-fda-drugs-anda077414-2006-03-07-fb0f45c75d7f"></a>
- **Drugs@FDA application ANDA077414 · original submission status AP · 2006-03-07 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077414%22&limit=1) (`fda-drugs-anda077414-2006-03-07-fb0f45c75d7f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077414." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda077414-v1 SHA-256: 74642911f374b2cd640a4fe13271a5e8e5e42c646a2971c123464304e64695d5.

---

<a id="fda-drugs-anda078271-v1"></a>

## Drugs@FDA application ANDA078271

> The official Drugs@FDA dataset lists original submission 1 for ANDA 078271 with status AP dated 2013-12-23, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda078271:v1`
- Evidence domain: Regulatory
- Date in source: 2013-12-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda078271/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda078271-v1
- Content SHA-256: `8c5c1a50d5f165317a3b06a2e09efa3618dd67d982b27cf5e57d76a5f5ea3b8c`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA078271 ([`fda-drugs-anda078271-2013-12-23-a937a47f1f67`](#source-fda-drugs-anda078271-2013-12-23-a937a47f1f67))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 078271 with status AP dated 2013-12-23, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda078271-2013-12-23-a937a47f1f67`](#source-fda-drugs-anda078271-2013-12-23-a937a47f1f67))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 078271 with status AP dated 2013-12-23, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda078271-2013-12-23-a937a47f1f67`](#source-fda-drugs-anda078271-2013-12-23-a937a47f1f67))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda078271-2013-12-23-a937a47f1f67`](#source-fda-drugs-anda078271-2013-12-23-a937a47f1f67))

### Sources

<a id="source-fda-drugs-anda078271-2013-12-23-a937a47f1f67"></a>
- **Drugs@FDA application ANDA078271 · original submission status AP · 2013-12-23 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA078271%22&limit=1) (`fda-drugs-anda078271-2013-12-23-a937a47f1f67`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA078271." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda078271-v1 SHA-256: 8c5c1a50d5f165317a3b06a2e09efa3618dd67d982b27cf5e57d76a5f5ea3b8c.

---

<a id="fda-drugs-anda091280-v1"></a>

## Drugs@FDA application ANDA091280

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091280 with status AP dated 2013-01-25, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091280:v1`
- Evidence domain: Regulatory
- Date in source: 2013-01-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091280/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda091280-v1
- Content SHA-256: `ac08a7ad22d86e137d85ab732a1cf3485c23b9080540526f2cdd19250880851a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091280 ([`fda-drugs-anda091280-2013-01-25-72eb5f3595c6`](#source-fda-drugs-anda091280-2013-01-25-72eb5f3595c6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091280 with status AP dated 2013-01-25, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda091280-2013-01-25-72eb5f3595c6`](#source-fda-drugs-anda091280-2013-01-25-72eb5f3595c6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091280 with status AP dated 2013-01-25, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda091280-2013-01-25-72eb5f3595c6`](#source-fda-drugs-anda091280-2013-01-25-72eb5f3595c6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091280-2013-01-25-72eb5f3595c6`](#source-fda-drugs-anda091280-2013-01-25-72eb5f3595c6))

### Sources

<a id="source-fda-drugs-anda091280-2013-01-25-72eb5f3595c6"></a>
- **Drugs@FDA application ANDA091280 · original submission status AP · 2013-01-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091280%22&limit=1) (`fda-drugs-anda091280-2013-01-25-72eb5f3595c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091280." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda091280-v1 SHA-256: ac08a7ad22d86e137d85ab732a1cf3485c23b9080540526f2cdd19250880851a.

---

<a id="fda-drugs-anda091345-v1"></a>

## Drugs@FDA application ANDA091345

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091345 with status AP dated 2017-10-03, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091345:v1`
- Evidence domain: Regulatory
- Date in source: 2017-10-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091345/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda091345-v1
- Content SHA-256: `3352c6ead7556d43f4d8f260587102fe1b911abc1af31b02d671d061c431240a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091345 ([`fda-drugs-anda091345-2017-10-03-5fd5e21bc103`](#source-fda-drugs-anda091345-2017-10-03-5fd5e21bc103))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091345 with status AP dated 2017-10-03, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda091345-2017-10-03-5fd5e21bc103`](#source-fda-drugs-anda091345-2017-10-03-5fd5e21bc103))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091345 with status AP dated 2017-10-03, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda091345-2017-10-03-5fd5e21bc103`](#source-fda-drugs-anda091345-2017-10-03-5fd5e21bc103))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091345-2017-10-03-5fd5e21bc103`](#source-fda-drugs-anda091345-2017-10-03-5fd5e21bc103))

### Sources

<a id="source-fda-drugs-anda091345-2017-10-03-5fd5e21bc103"></a>
- **Drugs@FDA application ANDA091345 · original submission status AP · 2017-10-03 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091345%22&limit=1) (`fda-drugs-anda091345-2017-10-03-5fd5e21bc103`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091345." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda091345-v1 SHA-256: 3352c6ead7556d43f4d8f260587102fe1b911abc1af31b02d671d061c431240a.

---

<a id="fda-drugs-anda091374-v1"></a>

## Drugs@FDA application ANDA091374

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091374 with status AP dated 2019-02-14, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091374:v1`
- Evidence domain: Regulatory
- Date in source: 2019-02-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091374/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda091374-v1
- Content SHA-256: `eb6ade52e177a89455a62a2e1e9f6e69b4a4bcf63fbf8ca2f4aa119e85b9fdc3`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091374 ([`fda-drugs-anda091374-2019-02-14-6cbacbf1e07c`](#source-fda-drugs-anda091374-2019-02-14-6cbacbf1e07c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091374 with status AP dated 2019-02-14, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda091374-2019-02-14-6cbacbf1e07c`](#source-fda-drugs-anda091374-2019-02-14-6cbacbf1e07c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091374 with status AP dated 2019-02-14, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda091374-2019-02-14-6cbacbf1e07c`](#source-fda-drugs-anda091374-2019-02-14-6cbacbf1e07c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091374-2019-02-14-6cbacbf1e07c`](#source-fda-drugs-anda091374-2019-02-14-6cbacbf1e07c))

### Sources

<a id="source-fda-drugs-anda091374-2019-02-14-6cbacbf1e07c"></a>
- **Drugs@FDA application ANDA091374 · original submission status AP · 2019-02-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091374%22&limit=1) (`fda-drugs-anda091374-2019-02-14-6cbacbf1e07c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091374." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda091374-v1 SHA-256: eb6ade52e177a89455a62a2e1e9f6e69b4a4bcf63fbf8ca2f4aa119e85b9fdc3.

---

<a id="fda-drugs-anda200653-v1"></a>

## Drugs@FDA application ANDA200653

> The official Drugs@FDA dataset lists original submission 1 for ANDA 200653 with status AP dated 2014-06-27, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda200653:v1`
- Evidence domain: Regulatory
- Date in source: 2014-06-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda200653/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda200653-v1
- Content SHA-256: `e06527198fb6399ddfdb0dcc39066a87b29733eb98b00faed3f685e376db6220`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA200653 ([`fda-drugs-anda200653-2014-06-27-5e4bb1a388ac`](#source-fda-drugs-anda200653-2014-06-27-5e4bb1a388ac))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 200653 with status AP dated 2014-06-27, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda200653-2014-06-27-5e4bb1a388ac`](#source-fda-drugs-anda200653-2014-06-27-5e4bb1a388ac))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 200653 with status AP dated 2014-06-27, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda200653-2014-06-27-5e4bb1a388ac`](#source-fda-drugs-anda200653-2014-06-27-5e4bb1a388ac))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda200653-2014-06-27-5e4bb1a388ac`](#source-fda-drugs-anda200653-2014-06-27-5e4bb1a388ac))

### Sources

<a id="source-fda-drugs-anda200653-2014-06-27-5e4bb1a388ac"></a>
- **Drugs@FDA application ANDA200653 · original submission status AP · 2014-06-27 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA200653%22&limit=1) (`fda-drugs-anda200653-2014-06-27-5e4bb1a388ac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA200653." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda200653-v1 SHA-256: e06527198fb6399ddfdb0dcc39066a87b29733eb98b00faed3f685e376db6220.

---

<a id="fda-drugs-anda201831-v1"></a>

## Drugs@FDA application ANDA201831

> The official Drugs@FDA dataset lists original submission 1 for ANDA 201831 with status AP dated 2015-05-28, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda201831:v1`
- Evidence domain: Regulatory
- Date in source: 2015-05-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda201831/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda201831-v1
- Content SHA-256: `a14b1b7decb42a90a721286701a9a3dbad213dafb36abab0857f2daf0d581ae6`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA201831 ([`fda-drugs-anda201831-2015-05-28-5eb20a92a588`](#source-fda-drugs-anda201831-2015-05-28-5eb20a92a588))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 201831 with status AP dated 2015-05-28, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda201831-2015-05-28-5eb20a92a588`](#source-fda-drugs-anda201831-2015-05-28-5eb20a92a588))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 201831 with status AP dated 2015-05-28, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda201831-2015-05-28-5eb20a92a588`](#source-fda-drugs-anda201831-2015-05-28-5eb20a92a588))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda201831-2015-05-28-5eb20a92a588`](#source-fda-drugs-anda201831-2015-05-28-5eb20a92a588))

### Sources

<a id="source-fda-drugs-anda201831-2015-05-28-5eb20a92a588"></a>
- **Drugs@FDA application ANDA201831 · original submission status AP · 2015-05-28 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA201831%22&limit=1) (`fda-drugs-anda201831-2015-05-28-5eb20a92a588`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA201831." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda201831-v1 SHA-256: a14b1b7decb42a90a721286701a9a3dbad213dafb36abab0857f2daf0d581ae6.

---

<a id="fda-drugs-anda204695-v1"></a>

## Drugs@FDA application ANDA204695

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204695 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204695:v1`
- Evidence domain: Regulatory
- Date in source: 2017-08-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204695/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda204695-v1
- Content SHA-256: `bf14a82b6b53370bb4e5d03ff644ec20c67b94f91f4c4d27026e14cee7ed5fa6`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204695 ([`fda-drugs-anda204695-2017-08-22-6798468d43cc`](#source-fda-drugs-anda204695-2017-08-22-6798468d43cc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204695 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda204695-2017-08-22-6798468d43cc`](#source-fda-drugs-anda204695-2017-08-22-6798468d43cc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204695 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda204695-2017-08-22-6798468d43cc`](#source-fda-drugs-anda204695-2017-08-22-6798468d43cc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204695-2017-08-22-6798468d43cc`](#source-fda-drugs-anda204695-2017-08-22-6798468d43cc))

### Sources

<a id="source-fda-drugs-anda204695-2017-08-22-6798468d43cc"></a>
- **Drugs@FDA application ANDA204695 · original submission status AP · 2017-08-22 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204695%22&limit=1) (`fda-drugs-anda204695-2017-08-22-6798468d43cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204695." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda204695-v1 SHA-256: bf14a82b6b53370bb4e5d03ff644ec20c67b94f91f4c4d27026e14cee7ed5fa6.

---

<a id="fda-drugs-anda204751-v1"></a>

## Drugs@FDA application ANDA204751

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204751 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204751:v1`
- Evidence domain: Regulatory
- Date in source: 2017-08-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204751/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda204751-v1
- Content SHA-256: `e146c22ecb88f6c720539c6e0910ba2c346b0d190511296d4e10d440a316de65`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204751 ([`fda-drugs-anda204751-2017-08-22-c0908de733eb`](#source-fda-drugs-anda204751-2017-08-22-c0908de733eb))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204751 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda204751-2017-08-22-c0908de733eb`](#source-fda-drugs-anda204751-2017-08-22-c0908de733eb))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204751 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda204751-2017-08-22-c0908de733eb`](#source-fda-drugs-anda204751-2017-08-22-c0908de733eb))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204751-2017-08-22-c0908de733eb`](#source-fda-drugs-anda204751-2017-08-22-c0908de733eb))

### Sources

<a id="source-fda-drugs-anda204751-2017-08-22-c0908de733eb"></a>
- **Drugs@FDA application ANDA204751 · original submission status AP · 2017-08-22 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204751%22&limit=1) (`fda-drugs-anda204751-2017-08-22-c0908de733eb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204751." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda204751-v1 SHA-256: e146c22ecb88f6c720539c6e0910ba2c346b0d190511296d4e10d440a316de65.

---

<a id="fda-drugs-anda207880-v1"></a>

## Drugs@FDA application ANDA207880

> The official Drugs@FDA dataset lists original submission 1 for ANDA 207880 with status AP dated 2017-05-26, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda207880:v1`
- Evidence domain: Regulatory
- Date in source: 2017-05-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda207880/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda207880-v1
- Content SHA-256: `f6385d9d44113ed9d0c4f3137247cf59d23c47bd7c445ecb1436032a8f27bbf5`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA207880 ([`fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa`](#source-fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 207880 with status AP dated 2017-05-26, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa`](#source-fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 207880 with status AP dated 2017-05-26, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa`](#source-fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa`](#source-fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa))

### Sources

<a id="source-fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa"></a>
- **Drugs@FDA application ANDA207880 · original submission status AP · 2017-05-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA207880%22&limit=1) (`fda-drugs-anda207880-2017-05-26-ccb02dd6bfaa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA207880." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda207880-v1 SHA-256: f6385d9d44113ed9d0c4f3137247cf59d23c47bd7c445ecb1436032a8f27bbf5.

---

<a id="fda-drugs-anda208357-v1"></a>

## Drugs@FDA application ANDA208357

> The official Drugs@FDA dataset lists original submission 1 for ANDA 208357 with status AP dated 2019-06-06, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda208357:v1`
- Evidence domain: Regulatory
- Date in source: 2019-06-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda208357/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda208357-v1
- Content SHA-256: `3567bce71d5b270b1d976742c20995376c5430da43a212a215bf3cec5d227b86`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA208357 ([`fda-drugs-anda208357-2019-06-06-a3478def19b0`](#source-fda-drugs-anda208357-2019-06-06-a3478def19b0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 208357 with status AP dated 2019-06-06, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda208357-2019-06-06-a3478def19b0`](#source-fda-drugs-anda208357-2019-06-06-a3478def19b0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 208357 with status AP dated 2019-06-06, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda208357-2019-06-06-a3478def19b0`](#source-fda-drugs-anda208357-2019-06-06-a3478def19b0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda208357-2019-06-06-a3478def19b0`](#source-fda-drugs-anda208357-2019-06-06-a3478def19b0))

### Sources

<a id="source-fda-drugs-anda208357-2019-06-06-a3478def19b0"></a>
- **Drugs@FDA application ANDA208357 · original submission status AP · 2019-06-06 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA208357%22&limit=1) (`fda-drugs-anda208357-2019-06-06-a3478def19b0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA208357." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda208357-v1 SHA-256: 3567bce71d5b270b1d976742c20995376c5430da43a212a215bf3cec5d227b86.

---

<a id="fda-drugs-anda210218-v1"></a>

## Drugs@FDA application ANDA210218

> The official Drugs@FDA dataset lists original submission 1 for ANDA 210218 with status AP dated 2020-02-14, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda210218:v1`
- Evidence domain: Regulatory
- Date in source: 2020-02-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda210218/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda210218-v1
- Content SHA-256: `779f68fad9a8ffffbeb1e132a76de498208107f56150078bbc295f5becc02adb`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA210218 ([`fda-drugs-anda210218-2020-02-14-3978905e053a`](#source-fda-drugs-anda210218-2020-02-14-3978905e053a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 210218 with status AP dated 2020-02-14, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda210218-2020-02-14-3978905e053a`](#source-fda-drugs-anda210218-2020-02-14-3978905e053a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 210218 with status AP dated 2020-02-14, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda210218-2020-02-14-3978905e053a`](#source-fda-drugs-anda210218-2020-02-14-3978905e053a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda210218-2020-02-14-3978905e053a`](#source-fda-drugs-anda210218-2020-02-14-3978905e053a))

### Sources

<a id="source-fda-drugs-anda210218-2020-02-14-3978905e053a"></a>
- **Drugs@FDA application ANDA210218 · original submission status AP · 2020-02-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA210218%22&limit=1) (`fda-drugs-anda210218-2020-02-14-3978905e053a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA210218." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda210218-v1 SHA-256: 779f68fad9a8ffffbeb1e132a76de498208107f56150078bbc295f5becc02adb.

---

<a id="fda-drugs-anda210223-v1"></a>

## Drugs@FDA application ANDA210223

> The official Drugs@FDA dataset lists original submission 1 for ANDA 210223 with status AP dated 2020-09-17, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda210223:v1`
- Evidence domain: Regulatory
- Date in source: 2020-09-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda210223/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda210223-v1
- Content SHA-256: `79f96c297b8593f8f0c2fa5a3f6a85f1f2f38a83ca1a2c6c0ece37085fdf8683`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA210223 ([`fda-drugs-anda210223-2020-09-17-75772fade14c`](#source-fda-drugs-anda210223-2020-09-17-75772fade14c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 210223 with status AP dated 2020-09-17, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda210223-2020-09-17-75772fade14c`](#source-fda-drugs-anda210223-2020-09-17-75772fade14c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 210223 with status AP dated 2020-09-17, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda210223-2020-09-17-75772fade14c`](#source-fda-drugs-anda210223-2020-09-17-75772fade14c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda210223-2020-09-17-75772fade14c`](#source-fda-drugs-anda210223-2020-09-17-75772fade14c))

### Sources

<a id="source-fda-drugs-anda210223-2020-09-17-75772fade14c"></a>
- **Drugs@FDA application ANDA210223 · original submission status AP · 2020-09-17 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA210223%22&limit=1) (`fda-drugs-anda210223-2020-09-17-75772fade14c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA210223." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda210223-v1 SHA-256: 79f96c297b8593f8f0c2fa5a3f6a85f1f2f38a83ca1a2c6c0ece37085fdf8683.

---

<a id="fda-drugs-anda210371-v1"></a>

## Drugs@FDA application ANDA210371

> The official Drugs@FDA dataset lists original submission 1 for ANDA 210371 with status AP dated 2019-01-28, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda210371:v1`
- Evidence domain: Regulatory
- Date in source: 2019-01-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda210371/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda210371-v1
- Content SHA-256: `4095248318fba02c65a87ba2808b5a4d05e2ee7d11151aaae78d2502cff7b352`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA210371 ([`fda-drugs-anda210371-2019-01-28-44d0cc869020`](#source-fda-drugs-anda210371-2019-01-28-44d0cc869020))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 210371 with status AP dated 2019-01-28, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda210371-2019-01-28-44d0cc869020`](#source-fda-drugs-anda210371-2019-01-28-44d0cc869020))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 210371 with status AP dated 2019-01-28, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda210371-2019-01-28-44d0cc869020`](#source-fda-drugs-anda210371-2019-01-28-44d0cc869020))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda210371-2019-01-28-44d0cc869020`](#source-fda-drugs-anda210371-2019-01-28-44d0cc869020))

### Sources

<a id="source-fda-drugs-anda210371-2019-01-28-44d0cc869020"></a>
- **Drugs@FDA application ANDA210371 · original submission status AP · 2019-01-28 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA210371%22&limit=1) (`fda-drugs-anda210371-2019-01-28-44d0cc869020`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA210371." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda210371-v1 SHA-256: 4095248318fba02c65a87ba2808b5a4d05e2ee7d11151aaae78d2502cff7b352.

---

<a id="fda-drugs-anda213095-v1"></a>

## Drugs@FDA application ANDA213095

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213095 with status AP dated 2024-03-21, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213095:v1`
- Evidence domain: Regulatory
- Date in source: 2024-03-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213095/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda213095-v1
- Content SHA-256: `6fca92f89aa71d8172ab00d4c47d8dd6dd3853f6e1a9e9795ec220c614f69441`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213095 ([`fda-drugs-anda213095-2024-03-21-6ce21448e566`](#source-fda-drugs-anda213095-2024-03-21-6ce21448e566))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213095 with status AP dated 2024-03-21, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda213095-2024-03-21-6ce21448e566`](#source-fda-drugs-anda213095-2024-03-21-6ce21448e566))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213095 with status AP dated 2024-03-21, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda213095-2024-03-21-6ce21448e566`](#source-fda-drugs-anda213095-2024-03-21-6ce21448e566))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213095-2024-03-21-6ce21448e566`](#source-fda-drugs-anda213095-2024-03-21-6ce21448e566))

### Sources

<a id="source-fda-drugs-anda213095-2024-03-21-6ce21448e566"></a>
- **Drugs@FDA application ANDA213095 · original submission status AP · 2024-03-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213095%22&limit=1) (`fda-drugs-anda213095-2024-03-21-6ce21448e566`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213095." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda213095-v1 SHA-256: 6fca92f89aa71d8172ab00d4c47d8dd6dd3853f6e1a9e9795ec220c614f69441.

---

<a id="fda-drugs-anda215961-v1"></a>

## Drugs@FDA application ANDA215961

> The official Drugs@FDA dataset lists original submission 1 for ANDA 215961 with status AP dated 2022-08-19, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda215961:v1`
- Evidence domain: Regulatory
- Date in source: 2022-08-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda215961/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda215961-v1
- Content SHA-256: `fc4a87553308cfdf098c868c0e7287027b597b2ca26f9207e90a5e87a1906190`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA215961 ([`fda-drugs-anda215961-2022-08-19-ea8a0c54b037`](#source-fda-drugs-anda215961-2022-08-19-ea8a0c54b037))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 215961 with status AP dated 2022-08-19, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda215961-2022-08-19-ea8a0c54b037`](#source-fda-drugs-anda215961-2022-08-19-ea8a0c54b037))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 215961 with status AP dated 2022-08-19, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda215961-2022-08-19-ea8a0c54b037`](#source-fda-drugs-anda215961-2022-08-19-ea8a0c54b037))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda215961-2022-08-19-ea8a0c54b037`](#source-fda-drugs-anda215961-2022-08-19-ea8a0c54b037))

### Sources

<a id="source-fda-drugs-anda215961-2022-08-19-ea8a0c54b037"></a>
- **Drugs@FDA application ANDA215961 · original submission status AP · 2022-08-19 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA215961%22&limit=1) (`fda-drugs-anda215961-2022-08-19-ea8a0c54b037`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA215961." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda215961-v1 SHA-256: fc4a87553308cfdf098c868c0e7287027b597b2ca26f9207e90a5e87a1906190.

---

<a id="fda-drugs-anda216904-v1"></a>

## Drugs@FDA application ANDA216904

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216904 with status AP dated 2023-03-20, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216904:v1`
- Evidence domain: Regulatory
- Date in source: 2023-03-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216904/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda216904-v1
- Content SHA-256: `d8704ca4b28bdb48dd97bb0ca557eb54b0479189c029000c15e6ab15ae93cd12`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216904 ([`fda-drugs-anda216904-2023-03-20-5c8b34b731e7`](#source-fda-drugs-anda216904-2023-03-20-5c8b34b731e7))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216904 with status AP dated 2023-03-20, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda216904-2023-03-20-5c8b34b731e7`](#source-fda-drugs-anda216904-2023-03-20-5c8b34b731e7))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216904 with status AP dated 2023-03-20, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda216904-2023-03-20-5c8b34b731e7`](#source-fda-drugs-anda216904-2023-03-20-5c8b34b731e7))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216904-2023-03-20-5c8b34b731e7`](#source-fda-drugs-anda216904-2023-03-20-5c8b34b731e7))

### Sources

<a id="source-fda-drugs-anda216904-2023-03-20-5c8b34b731e7"></a>
- **Drugs@FDA application ANDA216904 · original submission status AP · 2023-03-20 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216904%22&limit=1) (`fda-drugs-anda216904-2023-03-20-5c8b34b731e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216904." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda216904-v1 SHA-256: d8704ca4b28bdb48dd97bb0ca557eb54b0479189c029000c15e6ab15ae93cd12.

---

<a id="fda-drugs-anda216922-v1"></a>

## Drugs@FDA application ANDA216922

> The official Drugs@FDA dataset lists original submission 1 for ANDA 216922 with status AP dated 2022-11-16, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda216922:v1`
- Evidence domain: Regulatory
- Date in source: 2022-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda216922/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda216922-v1
- Content SHA-256: `975fda603a35b6316943eca5ce026a246ec4884504747059a4bf185b10ec057b`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA216922 ([`fda-drugs-anda216922-2022-11-16-eb51ce890721`](#source-fda-drugs-anda216922-2022-11-16-eb51ce890721))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 216922 with status AP dated 2022-11-16, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda216922-2022-11-16-eb51ce890721`](#source-fda-drugs-anda216922-2022-11-16-eb51ce890721))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 216922 with status AP dated 2022-11-16, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda216922-2022-11-16-eb51ce890721`](#source-fda-drugs-anda216922-2022-11-16-eb51ce890721))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda216922-2022-11-16-eb51ce890721`](#source-fda-drugs-anda216922-2022-11-16-eb51ce890721))

### Sources

<a id="source-fda-drugs-anda216922-2022-11-16-eb51ce890721"></a>
- **Drugs@FDA application ANDA216922 · original submission status AP · 2022-11-16 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA216922%22&limit=1) (`fda-drugs-anda216922-2022-11-16-eb51ce890721`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA216922." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda216922-v1 SHA-256: 975fda603a35b6316943eca5ce026a246ec4884504747059a4bf185b10ec057b.

---

<a id="fda-drugs-anda219981-v1"></a>

## Drugs@FDA application ANDA219981

> The official Drugs@FDA dataset lists original submission 1 for ANDA 219981 with status AP dated 2026-02-27, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda219981:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda219981/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda219981-v1
- Content SHA-256: `45ffa36553547f419464f800315d68ebca30cb714a51ed42379a592335109ddf`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA219981 ([`fda-drugs-anda219981-2026-02-27-a37b24461e4f`](#source-fda-drugs-anda219981-2026-02-27-a37b24461e4f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 219981 with status AP dated 2026-02-27, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda219981-2026-02-27-a37b24461e4f`](#source-fda-drugs-anda219981-2026-02-27-a37b24461e4f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 219981 with status AP dated 2026-02-27, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-anda219981-2026-02-27-a37b24461e4f`](#source-fda-drugs-anda219981-2026-02-27-a37b24461e4f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda219981-2026-02-27-a37b24461e4f`](#source-fda-drugs-anda219981-2026-02-27-a37b24461e4f))

### Sources

<a id="source-fda-drugs-anda219981-2026-02-27-a37b24461e4f"></a>
- **Drugs@FDA application ANDA219981 · original submission status AP · 2026-02-27 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA219981%22&limit=1) (`fda-drugs-anda219981-2026-02-27-a37b24461e4f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA219981." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-anda219981-v1 SHA-256: 45ffa36553547f419464f800315d68ebca30cb714a51ed42379a592335109ddf.

---

<a id="fda-drugs-nda017922-v1"></a>

## Drugs@FDA application NDA017922

> The official Drugs@FDA dataset lists original submission 1 for NDA 017922 with status AP dated 1978-02-21, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda017922:v1`
- Evidence domain: Regulatory
- Date in source: 1978-02-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda017922/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda017922-v1
- Content SHA-256: `3d96aa908d5929f803ee81ddc351a6399b9d9e1625ed2cafddbad3ad19844b56`

### Claims and source pins

#### Headline

Drugs@FDA application NDA017922 ([`fda-drugs-nda017922-1978-02-21-17379b52247b`](#source-fda-drugs-nda017922-1978-02-21-17379b52247b))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 017922 with status AP dated 1978-02-21, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda017922-1978-02-21-17379b52247b`](#source-fda-drugs-nda017922-1978-02-21-17379b52247b))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 017922 with status AP dated 1978-02-21, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda017922-1978-02-21-17379b52247b`](#source-fda-drugs-nda017922-1978-02-21-17379b52247b))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda017922-1978-02-21-17379b52247b`](#source-fda-drugs-nda017922-1978-02-21-17379b52247b))

### Sources

<a id="source-fda-drugs-nda017922-1978-02-21-17379b52247b"></a>
- **Drugs@FDA application NDA017922 · original submission status AP · 1978-02-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA017922%22&limit=1) (`fda-drugs-nda017922-1978-02-21-17379b52247b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA017922." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda017922-v1 SHA-256: 3d96aa908d5929f803ee81ddc351a6399b9d9e1625ed2cafddbad3ad19844b56.

---

<a id="fda-drugs-nda018938-v1"></a>

## Drugs@FDA application NDA018938

> The official Drugs@FDA dataset lists original submission 1 for NDA 018938 with status AP dated 1984-03-30, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda018938:v1`
- Evidence domain: Regulatory
- Date in source: 1984-03-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda018938/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda018938-v1
- Content SHA-256: `9640fc32f2808651e1b837cb539c3effc187b089803e9b6d0d6c728c50f5eec1`

### Claims and source pins

#### Headline

Drugs@FDA application NDA018938 ([`fda-drugs-nda018938-1984-03-30-e6d9b3752e27`](#source-fda-drugs-nda018938-1984-03-30-e6d9b3752e27))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 018938 with status AP dated 1984-03-30, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda018938-1984-03-30-e6d9b3752e27`](#source-fda-drugs-nda018938-1984-03-30-e6d9b3752e27))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 018938 with status AP dated 1984-03-30, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda018938-1984-03-30-e6d9b3752e27`](#source-fda-drugs-nda018938-1984-03-30-e6d9b3752e27))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda018938-1984-03-30-e6d9b3752e27`](#source-fda-drugs-nda018938-1984-03-30-e6d9b3752e27))

### Sources

<a id="source-fda-drugs-nda018938-1984-03-30-e6d9b3752e27"></a>
- **Drugs@FDA application NDA018938 · original submission status AP · 1984-03-30 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA018938%22&limit=1) (`fda-drugs-nda018938-1984-03-30-e6d9b3752e27`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA018938." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda018938-v1 SHA-256: 9640fc32f2808651e1b837cb539c3effc187b089803e9b6d0d6c728c50f5eec1.

---

<a id="fda-drugs-nda019776-v1"></a>

## Drugs@FDA application NDA019776

> The official Drugs@FDA dataset lists original submission 1 for NDA 019776 with status AP dated 1990-12-26, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019776:v1`
- Evidence domain: Regulatory
- Date in source: 1990-12-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019776/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda019776-v1
- Content SHA-256: `ac29238d77b9ba794ba03f0cd57bd92397420ad3b93beeb11747699e53f99c75`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019776 ([`fda-drugs-nda019776-1990-12-26-371ad58c6fd1`](#source-fda-drugs-nda019776-1990-12-26-371ad58c6fd1))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019776 with status AP dated 1990-12-26, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda019776-1990-12-26-371ad58c6fd1`](#source-fda-drugs-nda019776-1990-12-26-371ad58c6fd1))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019776 with status AP dated 1990-12-26, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda019776-1990-12-26-371ad58c6fd1`](#source-fda-drugs-nda019776-1990-12-26-371ad58c6fd1))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019776-1990-12-26-371ad58c6fd1`](#source-fda-drugs-nda019776-1990-12-26-371ad58c6fd1))

### Sources

<a id="source-fda-drugs-nda019776-1990-12-26-371ad58c6fd1"></a>
- **Drugs@FDA application NDA019776 · original submission status AP · 1990-12-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019776%22&limit=1) (`fda-drugs-nda019776-1990-12-26-371ad58c6fd1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019776." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda019776-v1 SHA-256: ac29238d77b9ba794ba03f0cd57bd92397420ad3b93beeb11747699e53f99c75.

---

<a id="fda-drugs-nda019955-v1"></a>

## Drugs@FDA application NDA019955

> The official Drugs@FDA dataset lists original submission 1 for NDA 019955 with status AP dated 1995-09-06, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019955:v1`
- Evidence domain: Regulatory
- Date in source: 1995-09-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019955/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda019955-v1
- Content SHA-256: `76aea5c6b8bfc091a024c0424aac1e0e27e0d69412b13fb7d07583a9fab9e293`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019955 ([`fda-drugs-nda019955-1995-09-06-4a202e76c11f`](#source-fda-drugs-nda019955-1995-09-06-4a202e76c11f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019955 with status AP dated 1995-09-06, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda019955-1995-09-06-4a202e76c11f`](#source-fda-drugs-nda019955-1995-09-06-4a202e76c11f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019955 with status AP dated 1995-09-06, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda019955-1995-09-06-4a202e76c11f`](#source-fda-drugs-nda019955-1995-09-06-4a202e76c11f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019955-1995-09-06-4a202e76c11f`](#source-fda-drugs-nda019955-1995-09-06-4a202e76c11f))

### Sources

<a id="source-fda-drugs-nda019955-1995-09-06-4a202e76c11f"></a>
- **Drugs@FDA application NDA019955 · original submission status AP · 1995-09-06 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019955%22&limit=1) (`fda-drugs-nda019955-1995-09-06-4a202e76c11f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019955." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda019955-v1 SHA-256: 76aea5c6b8bfc091a024c0424aac1e0e27e0d69412b13fb7d07583a9fab9e293.

---

<a id="fda-drugs-nda020355-v1"></a>

## Drugs@FDA application NDA020355

> The official Drugs@FDA dataset lists original submission 1 for NDA 020355 with status AP dated 1994-03-07, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020355:v1`
- Evidence domain: Regulatory
- Date in source: 1994-03-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020355/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda020355-v1
- Content SHA-256: `b172abb9309dc48e84ed82f3e9d7b679d9a1fa540b69b159a46ba458d3317a92`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020355 ([`fda-drugs-nda020355-1994-03-07-ab082a9c5a10`](#source-fda-drugs-nda020355-1994-03-07-ab082a9c5a10))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020355 with status AP dated 1994-03-07, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda020355-1994-03-07-ab082a9c5a10`](#source-fda-drugs-nda020355-1994-03-07-ab082a9c5a10))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020355 with status AP dated 1994-03-07, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda020355-1994-03-07-ab082a9c5a10`](#source-fda-drugs-nda020355-1994-03-07-ab082a9c5a10))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020355-1994-03-07-ab082a9c5a10`](#source-fda-drugs-nda020355-1994-03-07-ab082a9c5a10))

### Sources

<a id="source-fda-drugs-nda020355-1994-03-07-ab082a9c5a10"></a>
- **Drugs@FDA application NDA020355 · original submission status AP · 1994-03-07 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020355%22&limit=1) (`fda-drugs-nda020355-1994-03-07-ab082a9c5a10`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020355." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda020355-v1 SHA-256: b172abb9309dc48e84ed82f3e9d7b679d9a1fa540b69b159a46ba458d3317a92.

---

<a id="fda-drugs-nda021333-v1"></a>

## Drugs@FDA application NDA021333

> The official Drugs@FDA dataset lists original submission 1 for NDA 021333 with status AP dated 2002-09-16, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021333:v1`
- Evidence domain: Regulatory
- Date in source: 2002-09-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021333/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda021333-v1
- Content SHA-256: `ba5eb950cfaa0c2491206faf0831ca97650aef63e209adab0e0b73e4bda6b35c`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021333 ([`fda-drugs-nda021333-2002-09-16-725764a6a3fe`](#source-fda-drugs-nda021333-2002-09-16-725764a6a3fe))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021333 with status AP dated 2002-09-16, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda021333-2002-09-16-725764a6a3fe`](#source-fda-drugs-nda021333-2002-09-16-725764a6a3fe))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021333 with status AP dated 2002-09-16, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda021333-2002-09-16-725764a6a3fe`](#source-fda-drugs-nda021333-2002-09-16-725764a6a3fe))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021333-2002-09-16-725764a6a3fe`](#source-fda-drugs-nda021333-2002-09-16-725764a6a3fe))

### Sources

<a id="source-fda-drugs-nda021333-2002-09-16-725764a6a3fe"></a>
- **Drugs@FDA application NDA021333 · original submission status AP · 2002-09-16 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021333%22&limit=1) (`fda-drugs-nda021333-2002-09-16-725764a6a3fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021333." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda021333-v1 SHA-256: ba5eb950cfaa0c2491206faf0831ca97650aef63e209adab0e0b73e4bda6b35c.

---

<a id="fda-drugs-nda021795-v1"></a>

## Drugs@FDA application NDA021795

> The official Drugs@FDA dataset lists original submission 1 for NDA 021795 with status AP dated 2008-05-08, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021795:v1`
- Evidence domain: Regulatory
- Date in source: 2008-05-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021795/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda021795-v1
- Content SHA-256: `17a68a91dd936d77ba657ec5d9b7f279412683e1705f6af53634bc993d9bd602`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021795 ([`fda-drugs-nda021795-2008-05-08-d14dec9426dd`](#source-fda-drugs-nda021795-2008-05-08-d14dec9426dd))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021795 with status AP dated 2008-05-08, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda021795-2008-05-08-d14dec9426dd`](#source-fda-drugs-nda021795-2008-05-08-d14dec9426dd))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021795 with status AP dated 2008-05-08, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda021795-2008-05-08-d14dec9426dd`](#source-fda-drugs-nda021795-2008-05-08-d14dec9426dd))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021795-2008-05-08-d14dec9426dd`](#source-fda-drugs-nda021795-2008-05-08-d14dec9426dd))

### Sources

<a id="source-fda-drugs-nda021795-2008-05-08-d14dec9426dd"></a>
- **Drugs@FDA application NDA021795 · original submission status AP · 2008-05-08 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021795%22&limit=1) (`fda-drugs-nda021795-2008-05-08-d14dec9426dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021795." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda021795-v1 SHA-256: 17a68a91dd936d77ba657ec5d9b7f279412683e1705f6af53634bc993d9bd602.

---

<a id="fda-drugs-nda022517-v1"></a>

## Drugs@FDA application NDA022517

> The official Drugs@FDA dataset lists original submission 1 for NDA 022517 with status AP dated 2018-06-21, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda022517:v1`
- Evidence domain: Regulatory
- Date in source: 2018-06-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda022517/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda022517-v1
- Content SHA-256: `63ea8f5833f473d6009dd18c2c2f7665b5ca5f2eeda47fb84c025ac55742e09c`

### Claims and source pins

#### Headline

Drugs@FDA application NDA022517 ([`fda-drugs-nda022517-2018-06-21-a1f2561859af`](#source-fda-drugs-nda022517-2018-06-21-a1f2561859af))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 022517 with status AP dated 2018-06-21, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda022517-2018-06-21-a1f2561859af`](#source-fda-drugs-nda022517-2018-06-21-a1f2561859af))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 022517 with status AP dated 2018-06-21, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda022517-2018-06-21-a1f2561859af`](#source-fda-drugs-nda022517-2018-06-21-a1f2561859af))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda022517-2018-06-21-a1f2561859af`](#source-fda-drugs-nda022517-2018-06-21-a1f2561859af))

### Sources

<a id="source-fda-drugs-nda022517-2018-06-21-a1f2561859af"></a>
- **Drugs@FDA application NDA022517 · original submission status AP · 2018-06-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022517%22&limit=1) (`fda-drugs-nda022517-2018-06-21-a1f2561859af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA022517." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda022517-v1 SHA-256: 63ea8f5833f473d6009dd18c2c2f7665b5ca5f2eeda47fb84c025ac55742e09c.

---

<a id="fda-drugs-nda201656-v1"></a>

## Drugs@FDA application NDA201656

> The official Drugs@FDA dataset lists original submission 1 for NDA 201656 with status AP dated 2017-03-03, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda201656:v1`
- Evidence domain: Regulatory
- Date in source: 2017-03-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda201656/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda201656-v1
- Content SHA-256: `8c47441fd4760a85bfb3171e5871efb657e8b7e98b89125af95abf947f2ee1d8`

### Claims and source pins

#### Headline

Drugs@FDA application NDA201656 ([`fda-drugs-nda201656-2017-03-03-67a2ffe77956`](#source-fda-drugs-nda201656-2017-03-03-67a2ffe77956))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 201656 with status AP dated 2017-03-03, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda201656-2017-03-03-67a2ffe77956`](#source-fda-drugs-nda201656-2017-03-03-67a2ffe77956))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 201656 with status AP dated 2017-03-03, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda201656-2017-03-03-67a2ffe77956`](#source-fda-drugs-nda201656-2017-03-03-67a2ffe77956))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda201656-2017-03-03-67a2ffe77956`](#source-fda-drugs-nda201656-2017-03-03-67a2ffe77956))

### Sources

<a id="source-fda-drugs-nda201656-2017-03-03-67a2ffe77956"></a>
- **Drugs@FDA application NDA201656 · original submission status AP · 2017-03-03 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA201656%22&limit=1) (`fda-drugs-nda201656-2017-03-03-67a2ffe77956`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA201656." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda201656-v1 SHA-256: 8c47441fd4760a85bfb3171e5871efb657e8b7e98b89125af95abf947f2ee1d8.

---

<a id="fda-drugs-nda219873-v1"></a>

## Drugs@FDA application NDA219873

> The official Drugs@FDA dataset lists original submission 1 for NDA 219873 with status AP dated 2026-02-25, and names desmopressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda219873:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda219873/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda219873-v1
- Content SHA-256: `e944315fa2281d4b0578c73096a0c626689edac7da397af63f3b64961440e74f`

### Claims and source pins

#### Headline

Drugs@FDA application NDA219873 ([`fda-drugs-nda219873-2026-02-25-8171abfdd340`](#source-fda-drugs-nda219873-2026-02-25-8171abfdd340))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 219873 with status AP dated 2026-02-25, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda219873-2026-02-25-8171abfdd340`](#source-fda-drugs-nda219873-2026-02-25-8171abfdd340))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 219873 with status AP dated 2026-02-25, and names desmopressin acetate among the application record's active ingredients. ([`fda-drugs-nda219873-2026-02-25-8171abfdd340`](#source-fda-drugs-nda219873-2026-02-25-8171abfdd340))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda219873-2026-02-25-8171abfdd340`](#source-fda-drugs-nda219873-2026-02-25-8171abfdd340))

### Sources

<a id="source-fda-drugs-nda219873-2026-02-25-8171abfdd340"></a>
- **Drugs@FDA application NDA219873 · original submission status AP · 2026-02-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA219873%22&limit=1) (`fda-drugs-nda219873-2026-02-25-8171abfdd340`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA219873." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#fda-drugs-nda219873-v1 SHA-256: e944315fa2281d4b0578c73096a0c626689edac7da397af63f3b64961440e74f.

---

<a id="federal-register-2010-11038-v1"></a>

## Federal Register notice 2010-11038

> The Federal Register published notice 2010-11038, attributed to FDA and its parent HHS department, on 2010-05-11. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2010-11038:v1`
- Evidence domain: Regulatory
- Date in source: 2010-05-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2010-11038/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2010-11038-v1
- Content SHA-256: `0e460eaf020e138c61e6e6293f6b170ce4d23736846f99a29a836dc2fd7429a0`

### Claims and source pins

#### Headline

Federal Register notice 2010-11038 ([`federal-register-2010-11038-a724132bc4e0`](#source-federal-register-2010-11038-a724132bc4e0))

#### Summary

The Federal Register published notice 2010-11038, attributed to FDA and its parent HHS department, on 2010-05-11. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2010-11038-a724132bc4e0`](#source-federal-register-2010-11038-a724132bc4e0))

#### Paragraph 1

The Federal Register published notice 2010-11038, attributed to FDA and its parent HHS department, on 2010-05-11. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2010-11038-a724132bc4e0`](#source-federal-register-2010-11038-a724132bc4e0))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2010-11038-a724132bc4e0`](#source-federal-register-2010-11038-a724132bc4e0))

### Sources

<a id="source-federal-register-2010-11038-a724132bc4e0"></a>
- **Federal Register notice 2010-11038 · published 2010-05-11 · Pediatric Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2010-05-11/pdf/2010-11038.pdf) (`federal-register-2010-11038-a724132bc4e0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2010-11038." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2010-11038-v1 SHA-256: 0e460eaf020e138c61e6e6293f6b170ce4d23736846f99a29a836dc2fd7429a0.

---

<a id="federal-register-2012-30308-v1"></a>

## Federal Register notice 2012-30308

> The Federal Register published notice 2012-30308, attributed to FDA and its parent HHS department, on 2012-12-17. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2012-30308:v1`
- Evidence domain: Regulatory
- Date in source: 2012-12-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-30308/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2012-30308-v1
- Content SHA-256: `0cf715107fbc00b85b6b4814582386b3f7e4df1179afbe8bdb710070c5dc280f`

### Claims and source pins

#### Headline

Federal Register notice 2012-30308 ([`federal-register-2012-30308-ff4ae2a759aa`](#source-federal-register-2012-30308-ff4ae2a759aa))

#### Summary

The Federal Register published notice 2012-30308, attributed to FDA and its parent HHS department, on 2012-12-17. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2012-30308-ff4ae2a759aa`](#source-federal-register-2012-30308-ff4ae2a759aa))

#### Paragraph 1

The Federal Register published notice 2012-30308, attributed to FDA and its parent HHS department, on 2012-12-17. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2012-30308-ff4ae2a759aa`](#source-federal-register-2012-30308-ff4ae2a759aa))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-30308-ff4ae2a759aa`](#source-federal-register-2012-30308-ff4ae2a759aa))

### Sources

<a id="source-federal-register-2012-30308-ff4ae2a759aa"></a>
- **Federal Register notice 2012-30308 · published 2012-12-17 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-12-17/pdf/2012-30308.pdf) (`federal-register-2012-30308-ff4ae2a759aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-30308." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2012-30308-v1 SHA-256: 0cf715107fbc00b85b6b4814582386b3f7e4df1179afbe8bdb710070c5dc280f.

---

<a id="federal-register-2012-4037-v1"></a>

## Federal Register notice 2012-4037

> The Federal Register published notice 2012-4037, attributed to FDA and its parent HHS department, on 2012-02-22. Its official title is “Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2012-4037:v1`
- Evidence domain: Regulatory
- Date in source: 2012-02-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-4037/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2012-4037-v1
- Content SHA-256: `b88ffed2182d63f3aa14a0889975bcab0b033e3c19f048f5e3dd8c47eca92808`

### Claims and source pins

#### Headline

Federal Register notice 2012-4037 ([`federal-register-2012-4037-7107b4c1eaf5`](#source-federal-register-2012-4037-7107b4c1eaf5))

#### Summary

The Federal Register published notice 2012-4037, attributed to FDA and its parent HHS department, on 2012-02-22. Its official title is “Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2012-4037-7107b4c1eaf5`](#source-federal-register-2012-4037-7107b4c1eaf5))

#### Paragraph 1

The Federal Register published notice 2012-4037, attributed to FDA and its parent HHS department, on 2012-02-22. Its official title is “Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2012-4037-7107b4c1eaf5`](#source-federal-register-2012-4037-7107b4c1eaf5))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-4037-7107b4c1eaf5`](#source-federal-register-2012-4037-7107b4c1eaf5))

### Sources

<a id="source-federal-register-2012-4037-7107b4c1eaf5"></a>
- **Federal Register notice 2012-4037 · published 2012-02-22 · Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-02-22/pdf/2012-4037.pdf) (`federal-register-2012-4037-7107b4c1eaf5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-4037." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2012-4037-v1 SHA-256: b88ffed2182d63f3aa14a0889975bcab0b033e3c19f048f5e3dd8c47eca92808.

---

<a id="federal-register-2014-28702-v1"></a>

## Federal Register notice 2014-28702

> The Federal Register published notice 2014-28702, attributed to FDA and its parent HHS department, on 2014-12-09. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2014-28702:v1`
- Evidence domain: Regulatory
- Date in source: 2014-12-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-28702/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2014-28702-v1
- Content SHA-256: `ea1d655134e2cacebfb4545aa8a1a1336d4a86781b913b0a35f1dc2256a0b533`

### Claims and source pins

#### Headline

Federal Register notice 2014-28702 ([`federal-register-2014-28702-dd5673740e70`](#source-federal-register-2014-28702-dd5673740e70))

#### Summary

The Federal Register published notice 2014-28702, attributed to FDA and its parent HHS department, on 2014-12-09. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2014-28702-dd5673740e70`](#source-federal-register-2014-28702-dd5673740e70))

#### Paragraph 1

The Federal Register published notice 2014-28702, attributed to FDA and its parent HHS department, on 2014-12-09. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2014-28702-dd5673740e70`](#source-federal-register-2014-28702-dd5673740e70))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-28702-dd5673740e70`](#source-federal-register-2014-28702-dd5673740e70))

### Sources

<a id="source-federal-register-2014-28702-dd5673740e70"></a>
- **Federal Register notice 2014-28702 · published 2014-12-09 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-12-09/pdf/2014-28702.pdf) (`federal-register-2014-28702-dd5673740e70`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-28702." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2014-28702-v1 SHA-256: ea1d655134e2cacebfb4545aa8a1a1336d4a86781b913b0a35f1dc2256a0b533.

---

<a id="federal-register-2016-14418-v1"></a>

## Federal Register notice 2016-14418

> The Federal Register published notice 2016-14418, attributed to FDA and its parent HHS department, on 2016-06-20. Its official title is “Bone, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2016-14418:v1`
- Evidence domain: Regulatory
- Date in source: 2016-06-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-14418/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2016-14418-v1
- Content SHA-256: `968df1db996e6801729374d9d3ec99640f8c4d5ded1f32ca2a3a047b9ea276e7`

### Claims and source pins

#### Headline

Federal Register notice 2016-14418 ([`federal-register-2016-14418-9c414544bd85`](#source-federal-register-2016-14418-9c414544bd85))

#### Summary

The Federal Register published notice 2016-14418, attributed to FDA and its parent HHS department, on 2016-06-20. Its official title is “Bone, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2016-14418-9c414544bd85`](#source-federal-register-2016-14418-9c414544bd85))

#### Paragraph 1

The Federal Register published notice 2016-14418, attributed to FDA and its parent HHS department, on 2016-06-20. Its official title is “Bone, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2016-14418-9c414544bd85`](#source-federal-register-2016-14418-9c414544bd85))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-14418-9c414544bd85`](#source-federal-register-2016-14418-9c414544bd85))

### Sources

<a id="source-federal-register-2016-14418-9c414544bd85"></a>
- **Federal Register notice 2016-14418 · published 2016-06-20 · Bone, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-06-20/pdf/2016-14418.pdf) (`federal-register-2016-14418-9c414544bd85`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2016-14418." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2016-14418-v1 SHA-256: 968df1db996e6801729374d9d3ec99640f8c4d5ded1f32ca2a3a047b9ea276e7.

---

<a id="federal-register-2017-16581-v1"></a>

## Federal Register notice 2017-16581

> The Federal Register published notice 2017-16581, attributed to FDA and its parent HHS department, on 2017-08-07. Its official title is “Product-Specific Guidances; Final Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2017-16581:v1`
- Evidence domain: Regulatory
- Date in source: 2017-08-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2017-16581/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2017-16581-v1
- Content SHA-256: `e0ae846ddb9ea6b7ef8703476f4c4f27c8f23433992fc9c231a303b4e3fdf110`

### Claims and source pins

#### Headline

Federal Register notice 2017-16581 ([`federal-register-2017-16581-bcb70d2ba23c`](#source-federal-register-2017-16581-bcb70d2ba23c))

#### Summary

The Federal Register published notice 2017-16581, attributed to FDA and its parent HHS department, on 2017-08-07. Its official title is “Product-Specific Guidances; Final Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2017-16581-bcb70d2ba23c`](#source-federal-register-2017-16581-bcb70d2ba23c))

#### Paragraph 1

The Federal Register published notice 2017-16581, attributed to FDA and its parent HHS department, on 2017-08-07. Its official title is “Product-Specific Guidances; Final Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2017-16581-bcb70d2ba23c`](#source-federal-register-2017-16581-bcb70d2ba23c))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2017-16581-bcb70d2ba23c`](#source-federal-register-2017-16581-bcb70d2ba23c))

### Sources

<a id="source-federal-register-2017-16581-bcb70d2ba23c"></a>
- **Federal Register notice 2017-16581 · published 2017-08-07 · Product-Specific Guidances; Final Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2017-08-07/pdf/2017-16581.pdf) (`federal-register-2017-16581-bcb70d2ba23c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2017-16581." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2017-16581-v1 SHA-256: e0ae846ddb9ea6b7ef8703476f4c4f27c8f23433992fc9c231a303b4e3fdf110.

---

<a id="federal-register-2019-10165-v1"></a>

## Federal Register notice 2019-10165

> The Federal Register published notice 2019-10165, attributed to FDA and its parent HHS department, on 2019-05-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2019-10165:v1`
- Evidence domain: Regulatory
- Date in source: 2019-05-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-10165/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2019-10165-v1
- Content SHA-256: `20988220c71acfc6c28fd3bb1fa9fe9b5746e6d8d613b05c5978a008b9725afe`

### Claims and source pins

#### Headline

Federal Register notice 2019-10165 ([`federal-register-2019-10165-66f2a26b6502`](#source-federal-register-2019-10165-66f2a26b6502))

#### Summary

The Federal Register published notice 2019-10165, attributed to FDA and its parent HHS department, on 2019-05-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2019-10165-66f2a26b6502`](#source-federal-register-2019-10165-66f2a26b6502))

#### Paragraph 1

The Federal Register published notice 2019-10165, attributed to FDA and its parent HHS department, on 2019-05-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2019-10165-66f2a26b6502`](#source-federal-register-2019-10165-66f2a26b6502))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-10165-66f2a26b6502`](#source-federal-register-2019-10165-66f2a26b6502))

### Sources

<a id="source-federal-register-2019-10165-66f2a26b6502"></a>
- **Federal Register notice 2019-10165 · published 2019-05-16 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-05-16/pdf/2019-10165.pdf) (`federal-register-2019-10165-66f2a26b6502`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2019-10165." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2019-10165-v1 SHA-256: 20988220c71acfc6c28fd3bb1fa9fe9b5746e6d8d613b05c5978a008b9725afe.

---

<a id="federal-register-2023-02442-v1"></a>

## Federal Register notice 2023-02442

> The Federal Register published notice 2023-02442, attributed to FDA and its parent HHS department, on 2023-02-06. Its official title is “Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2023-02442:v1`
- Evidence domain: Regulatory
- Date in source: 2023-02-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-02442/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2023-02442-v1
- Content SHA-256: `45cb671f220edbed10abe0a33f3dc8f0c09da94bfa59273a02b3e3490588dccc`

### Claims and source pins

#### Headline

Federal Register notice 2023-02442 ([`federal-register-2023-02442-834133c84057`](#source-federal-register-2023-02442-834133c84057))

#### Summary

The Federal Register published notice 2023-02442, attributed to FDA and its parent HHS department, on 2023-02-06. Its official title is “Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2023-02442-834133c84057`](#source-federal-register-2023-02442-834133c84057))

#### Paragraph 1

The Federal Register published notice 2023-02442, attributed to FDA and its parent HHS department, on 2023-02-06. Its official title is “Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2023-02442-834133c84057`](#source-federal-register-2023-02442-834133c84057))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-02442-834133c84057`](#source-federal-register-2023-02442-834133c84057))

### Sources

<a id="source-federal-register-2023-02442-834133c84057"></a>
- **Federal Register notice 2023-02442 · published 2023-02-06 · Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-02-06/pdf/2023-02442.pdf) (`federal-register-2023-02442-834133c84057`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-02442." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2023-02442-v1 SHA-256: 45cb671f220edbed10abe0a33f3dc8f0c09da94bfa59273a02b3e3490588dccc.

---

<a id="federal-register-2024-25391-v1"></a>

## Federal Register notice 2024-25391

> The Federal Register published notice 2024-25391, attributed to FDA and its parent HHS department, on 2024-10-31. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2024-25391:v1`
- Evidence domain: Regulatory
- Date in source: 2024-10-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-25391/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2024-25391-v1
- Content SHA-256: `c5356891d6e0ab98ba2e328ab1913e0352e4807b54d7ced1e5406e5d9fb57fdf`

### Claims and source pins

#### Headline

Federal Register notice 2024-25391 ([`federal-register-2024-25391-8e5b13d78967`](#source-federal-register-2024-25391-8e5b13d78967))

#### Summary

The Federal Register published notice 2024-25391, attributed to FDA and its parent HHS department, on 2024-10-31. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2024-25391-8e5b13d78967`](#source-federal-register-2024-25391-8e5b13d78967))

#### Paragraph 1

The Federal Register published notice 2024-25391, attributed to FDA and its parent HHS department, on 2024-10-31. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2024-25391-8e5b13d78967`](#source-federal-register-2024-25391-8e5b13d78967))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-25391-8e5b13d78967`](#source-federal-register-2024-25391-8e5b13d78967))

### Sources

<a id="source-federal-register-2024-25391-8e5b13d78967"></a>
- **Federal Register notice 2024-25391 · published 2024-10-31 · Product-Specific Guidances; Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-10-31/pdf/2024-25391.pdf) (`federal-register-2024-25391-8e5b13d78967`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-25391." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2024-25391-v1 SHA-256: c5356891d6e0ab98ba2e328ab1913e0352e4807b54d7ced1e5406e5d9fb57fdf.

---

<a id="federal-register-2024-26913-v1"></a>

## Federal Register notice 2024-26913

> The Federal Register published notice 2024-26913, attributed to FDA and its parent HHS department, on 2024-11-19. Its official title is “Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-2024-26913:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-26913/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2024-26913-v1
- Content SHA-256: `e848fc244c41aad38d138a05ec684e39fba42667255e1d161e8659f0776025ae`

### Claims and source pins

#### Headline

Federal Register notice 2024-26913 ([`federal-register-2024-26913-0ed85cba998d`](#source-federal-register-2024-26913-0ed85cba998d))

#### Summary

The Federal Register published notice 2024-26913, attributed to FDA and its parent HHS department, on 2024-11-19. Its official title is “Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2024-26913-0ed85cba998d`](#source-federal-register-2024-26913-0ed85cba998d))

#### Paragraph 1

The Federal Register published notice 2024-26913, attributed to FDA and its parent HHS department, on 2024-11-19. Its official title is “Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-2024-26913-0ed85cba998d`](#source-federal-register-2024-26913-0ed85cba998d))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-26913-0ed85cba998d`](#source-federal-register-2024-26913-0ed85cba998d))

### Sources

<a id="source-federal-register-2024-26913-0ed85cba998d"></a>
- **Federal Register notice 2024-26913 · published 2024-11-19 · Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-11-19/pdf/2024-26913.pdf) (`federal-register-2024-26913-0ed85cba998d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-26913." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-2024-26913-v1 SHA-256: e848fc244c41aad38d138a05ec684e39fba42667255e1d161e8659f0776025ae.

---

<a id="federal-register-97-30614-v1"></a>

## Federal Register notice 97-30614

> The Federal Register published notice 97-30614, attributed to FDA and its parent HHS department, on 1997-11-21. Its official title is “Determination That Desmopressin Acetate Nasal Solution 0.01% (for Refrigerated Storage) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-97-30614:v1`
- Evidence domain: Regulatory
- Date in source: 1997-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-97-30614/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-97-30614-v1
- Content SHA-256: `facc90d8c18dcd46102e510b10d302d9ef030faf8cc4d3557b79b1076c4cca74`

### Claims and source pins

#### Headline

Federal Register notice 97-30614 ([`federal-register-97-30614-7a8e6f0763d7`](#source-federal-register-97-30614-7a8e6f0763d7))

#### Summary

The Federal Register published notice 97-30614, attributed to FDA and its parent HHS department, on 1997-11-21. Its official title is “Determination That Desmopressin Acetate Nasal Solution 0.01% (for Refrigerated Storage) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-97-30614-7a8e6f0763d7`](#source-federal-register-97-30614-7a8e6f0763d7))

#### Paragraph 1

The Federal Register published notice 97-30614, attributed to FDA and its parent HHS department, on 1997-11-21. Its official title is “Determination That Desmopressin Acetate Nasal Solution 0.01% (for Refrigerated Storage) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-97-30614-7a8e6f0763d7`](#source-federal-register-97-30614-7a8e6f0763d7))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-97-30614-7a8e6f0763d7`](#source-federal-register-97-30614-7a8e6f0763d7))

### Sources

<a id="source-federal-register-97-30614-7a8e6f0763d7"></a>
- **Federal Register notice 97-30614 · published 1997-11-21 · Determination That Desmopressin Acetate Nasal Solution 0.01% (for Refrigerated Storage) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1997-11-21/pdf/97-30614.pdf) (`federal-register-97-30614-7a8e6f0763d7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 97-30614." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-97-30614-v1 SHA-256: facc90d8c18dcd46102e510b10d302d9ef030faf8cc4d3557b79b1076c4cca74.

---

<a id="federal-register-e8-24050-v1"></a>

## Federal Register rule E8-24050

> The Federal Register published rule E8-24050, attributed to FDA and its parent HHS department, on 2008-10-09. Its official title is “Distribution of Certain Drug Products by Registered Blood Establishments and Comprehensive Hemophilia Diagnostic Treatment Centers That Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-e8-24050:v1`
- Evidence domain: Regulatory
- Date in source: 2008-10-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-e8-24050/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-e8-24050-v1
- Content SHA-256: `322cb87a66cca22d2eee8405bee636a66cf56c3e3b923e502564905a9099c252`

### Claims and source pins

#### Headline

Federal Register rule E8-24050 ([`federal-register-e8-24050-2650bcffd1b0`](#source-federal-register-e8-24050-2650bcffd1b0))

#### Summary

The Federal Register published rule E8-24050, attributed to FDA and its parent HHS department, on 2008-10-09. Its official title is “Distribution of Certain Drug Products by Registered Blood Establishments and Comprehensive Hemophilia Diagnostic Treatment Centers That Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-e8-24050-2650bcffd1b0`](#source-federal-register-e8-24050-2650bcffd1b0))

#### Paragraph 1

The Federal Register published rule E8-24050, attributed to FDA and its parent HHS department, on 2008-10-09. Its official title is “Distribution of Certain Drug Products by Registered Blood Establishments and Comprehensive Hemophilia Diagnostic Treatment Centers That Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-e8-24050-2650bcffd1b0`](#source-federal-register-e8-24050-2650bcffd1b0))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e8-24050-2650bcffd1b0`](#source-federal-register-e8-24050-2650bcffd1b0))

### Sources

<a id="source-federal-register-e8-24050-2650bcffd1b0"></a>
- **Federal Register rule E8-24050 · published 2008-10-09 · Distribution of Certain Drug Products by Registered Blood Establishments and Comprehensive Hemophilia Diagnostic Treatment Centers That Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2008-10-09/pdf/E8-24050.pdf) (`federal-register-e8-24050-2650bcffd1b0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule E8-24050." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-e8-24050-v1 SHA-256: 322cb87a66cca22d2eee8405bee636a66cf56c3e3b923e502564905a9099c252.

---

<a id="federal-register-e9-28593-v1"></a>

## Federal Register notice E9-28593

> The Federal Register published notice E9-28593, attributed to FDA and its parent HHS department, on 2009-12-01. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

- Evidence object: `story:federal-register-e9-28593:v1`
- Evidence domain: Regulatory
- Date in source: 2009-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-e9-28593/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-e9-28593-v1
- Content SHA-256: `cfdf60b17abed228b125c3f0da11e89e417f528bcf71c566980696efa738ecd9`

### Claims and source pins

#### Headline

Federal Register notice E9-28593 ([`federal-register-e9-28593-fc94ea024b8f`](#source-federal-register-e9-28593-fc94ea024b8f))

#### Summary

The Federal Register published notice E9-28593, attributed to FDA and its parent HHS department, on 2009-12-01. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-e9-28593-fc94ea024b8f`](#source-federal-register-e9-28593-fc94ea024b8f))

#### Paragraph 1

The Federal Register published notice E9-28593, attributed to FDA and its parent HHS department, on 2009-12-01. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin. ([`federal-register-e9-28593-fc94ea024b8f`](#source-federal-register-e9-28593-fc94ea024b8f))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e9-28593-fc94ea024b8f`](#source-federal-register-e9-28593-fc94ea024b8f))

### Sources

<a id="source-federal-register-e9-28593-fc94ea024b8f"></a>
- **Federal Register notice E9-28593 · published 2009-12-01 · Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2009-12-01/pdf/E9-28593.pdf) (`federal-register-e9-28593-fc94ea024b8f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E9-28593." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#federal-register-e9-28593-v1 SHA-256: cfdf60b17abed228b125c3f0da11e89e417f528bcf71c566980696efa738ecd9.

---

<a id="pubmed-pmid-27117753-desmopressin-v1"></a>

## Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial.

> PubMed lists PMID 27117753 in Acta anaesthesiologica Scandinavica as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2016-04-27 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27117753-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-02-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27117753-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-27117753-desmopressin-v1
- Content SHA-256: `619f65f13b10b543dace19633257af53c26bd1b725093a94791d3fa03965f419`

### Claims and source pins

#### Headline

Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial. ([`pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e`](#source-pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e))

#### Summary

PubMed lists PMID 27117753 in Acta anaesthesiologica Scandinavica as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2016-04-27 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e`](#source-pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e))

#### Paragraph 1

PubMed lists PMID 27117753 in Acta anaesthesiologica Scandinavica as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2016-04-27 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e`](#source-pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e`](#source-pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e))

### Sources

<a id="source-pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e"></a>
- **Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial. · retained source version 1:2017-02-09:current:b9d4cd93718e7ab7696e6e0897d81352bf024b23ca1a7b65737e3d3148cbcb39** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27117753/) (`pubmed-observation-pmid-27117753-2017-02-09-b9d4cd93718e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-27117753-desmopressin-v1 SHA-256: 619f65f13b10b543dace19633257af53c26bd1b725093a94791d3fa03965f419.

---

<a id="pubmed-pmid-27343233-desmopressin-v1"></a>

## Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis.

> PubMed lists PMID 27343233 in Pediatrics as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-06-24 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27343233-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27343233-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-27343233-desmopressin-v1
- Content SHA-256: `c3ecf271ac56fe84805f33c5339009200ab84b3a89ace734b64f7ee39fe1a204`

### Claims and source pins

#### Headline

Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis. ([`pubmed-observation-pmid-27343233-2025-06-26-2784f398a088`](#source-pubmed-observation-pmid-27343233-2025-06-26-2784f398a088))

#### Summary

PubMed lists PMID 27343233 in Pediatrics as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-06-24 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27343233-2025-06-26-2784f398a088`](#source-pubmed-observation-pmid-27343233-2025-06-26-2784f398a088))

#### Paragraph 1

PubMed lists PMID 27343233 in Pediatrics as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-06-24 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27343233-2025-06-26-2784f398a088`](#source-pubmed-observation-pmid-27343233-2025-06-26-2784f398a088))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27343233-2025-06-26-2784f398a088`](#source-pubmed-observation-pmid-27343233-2025-06-26-2784f398a088))

### Sources

<a id="source-pubmed-observation-pmid-27343233-2025-06-26-2784f398a088"></a>
- **Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis. · retained source version 1:2025-06-26:current:2784f398a08807bc0fa4faf78c60003952ac6e98011360945aa81e5a43cc637e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27343233/) (`pubmed-observation-pmid-27343233-2025-06-26-2784f398a088`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-27343233-desmopressin-v1 SHA-256: c3ecf271ac56fe84805f33c5339009200ab84b3a89ace734b64f7ee39fe1a204.

---

<a id="pubmed-pmid-27443694-desmopressin-v1"></a>

## Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.

> PubMed lists PMID 27443694 in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis as Journal Article, Review, with publication-date metadata of 2016-07-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27443694-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27443694-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-27443694-desmopressin-v1
- Content SHA-256: `ccaf09422220b62389bb46ccd8a732d54101d7c3085ebe69b658af7167ecb393`

### Claims and source pins

#### Headline

Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test. ([`pubmed-observation-pmid-27443694-2022-03-18-5027642b080f`](#source-pubmed-observation-pmid-27443694-2022-03-18-5027642b080f))

#### Summary

PubMed lists PMID 27443694 in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis as Journal Article, Review, with publication-date metadata of 2016-07-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27443694-2022-03-18-5027642b080f`](#source-pubmed-observation-pmid-27443694-2022-03-18-5027642b080f))

#### Paragraph 1

PubMed lists PMID 27443694 in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis as Journal Article, Review, with publication-date metadata of 2016-07-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27443694-2022-03-18-5027642b080f`](#source-pubmed-observation-pmid-27443694-2022-03-18-5027642b080f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27443694-2022-03-18-5027642b080f`](#source-pubmed-observation-pmid-27443694-2022-03-18-5027642b080f))

### Sources

<a id="source-pubmed-observation-pmid-27443694-2022-03-18-5027642b080f"></a>
- **Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test. · retained source version 1:2022-03-18:current:5027642b080ff4dfbf8eddf07bb9a123c4bda9072ff2d0c4959ade492c260c08** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27443694/) (`pubmed-observation-pmid-27443694-2022-03-18-5027642b080f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-27443694-desmopressin-v1 SHA-256: ccaf09422220b62389bb46ccd8a732d54101d7c3085ebe69b658af7167ecb393.

---

<a id="pubmed-pmid-27787700-desmopressin-v1"></a>

## Combination treatment of nocturnal enuresis with desmopressin and indomethacin.

> PubMed lists PMID 27787700 in Pediatric nephrology (Berlin, Germany) as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-10-27 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27787700-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27787700-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-27787700-desmopressin-v1
- Content SHA-256: `8be7e2e1ac0b170a2581098299a6a45e173809d4e1354b0e00783cd3c0aacf2f`

### Claims and source pins

#### Headline

Combination treatment of nocturnal enuresis with desmopressin and indomethacin. ([`pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece`](#source-pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece))

#### Summary

PubMed lists PMID 27787700 in Pediatric nephrology (Berlin, Germany) as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-10-27 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece`](#source-pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece))

#### Paragraph 1

PubMed lists PMID 27787700 in Pediatric nephrology (Berlin, Germany) as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-10-27 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece`](#source-pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece`](#source-pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece))

### Sources

<a id="source-pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece"></a>
- **Combination treatment of nocturnal enuresis with desmopressin and indomethacin. · retained source version 1:2018-11-13:current:18fa92250ece0018f3a416880e91403894f1727ef455f25d8e503b2964a77b33** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27787700/) (`pubmed-observation-pmid-27787700-2018-11-13-18fa92250ece`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combination treatment of nocturnal enuresis with desmopressin and indomethacin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-27787700-desmopressin-v1 SHA-256: 8be7e2e1ac0b170a2581098299a6a45e173809d4e1354b0e00783cd3c0aacf2f.

---

<a id="pubmed-pmid-29055129-desmopressin-v1"></a>

## Desmopressin for treating nocturia in men.

> PubMed lists PMID 29055129 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S., Systematic Review, with publication-date metadata of 2017-10-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29055129-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29055129-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-29055129-desmopressin-v1
- Content SHA-256: `2333b8a4d7c72295c8425806c5c29b85c58829e921d57847d48961d7b45fdcc1`

### Claims and source pins

#### Headline

Desmopressin for treating nocturia in men. ([`pubmed-observation-pmid-29055129-2025-06-23-dd275c524496`](#source-pubmed-observation-pmid-29055129-2025-06-23-dd275c524496))

#### Summary

PubMed lists PMID 29055129 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S., Systematic Review, with publication-date metadata of 2017-10-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29055129-2025-06-23-dd275c524496`](#source-pubmed-observation-pmid-29055129-2025-06-23-dd275c524496))

#### Paragraph 1

PubMed lists PMID 29055129 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S., Systematic Review, with publication-date metadata of 2017-10-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29055129-2025-06-23-dd275c524496`](#source-pubmed-observation-pmid-29055129-2025-06-23-dd275c524496))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29055129-2025-06-23-dd275c524496`](#source-pubmed-observation-pmid-29055129-2025-06-23-dd275c524496))

### Sources

<a id="source-pubmed-observation-pmid-29055129-2025-06-23-dd275c524496"></a>
- **Desmopressin for treating nocturia in men. · retained source version 1:2025-06-23:current:dd275c5244966166a0754507cf7943e07e02fafaddca620fd5e9f1fdc18d9510** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29055129/) (`pubmed-observation-pmid-29055129-2025-06-23-dd275c524496`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin for treating nocturia in men." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-29055129-desmopressin-v1 SHA-256: 2333b8a4d7c72295c8425806c5c29b85c58829e921d57847d48961d7b45fdcc1.

---

<a id="pubmed-pmid-29489052-desmopressin-v1"></a>

## Desmopressin for treating nocturia in men.

> PubMed lists PMID 29489052 in BJU international as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2018-03-26 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29489052-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-03-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29489052-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-29489052-desmopressin-v1
- Content SHA-256: `1ee0533136bbd855f77401da48ddbdb9b1c05f7603bc6929f10754db97d616fc`

### Claims and source pins

#### Headline

Desmopressin for treating nocturia in men. ([`pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322`](#source-pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322))

#### Summary

PubMed lists PMID 29489052 in BJU international as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2018-03-26 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322`](#source-pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322))

#### Paragraph 1

PubMed lists PMID 29489052 in BJU international as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2018-03-26 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322`](#source-pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322`](#source-pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322))

### Sources

<a id="source-pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322"></a>
- **Desmopressin for treating nocturia in men. · retained source version 1:2019-03-26:current:1bc79e101322512d8c6f9117488f4411efb832f623139dfd32666e7df9cb33bc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29489052/) (`pubmed-observation-pmid-29489052-2019-03-26-1bc79e101322`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin for treating nocturia in men." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-29489052-desmopressin-v1 SHA-256: 1ee0533136bbd855f77401da48ddbdb9b1c05f7603bc6929f10754db97d616fc.

---

<a id="pubmed-pmid-29492635-desmopressin-v1"></a>

## \[Treatment of nocturia in men with desmopressin\].

> PubMed lists PMID 29492635 in Der Urologe. Ausg. A as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29492635-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29492635-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-29492635-desmopressin-v1
- Content SHA-256: `a24f19ebf50a7e374f21f98a393c70c30881addc95787ce0460efabe63315bd7`

### Claims and source pins

#### Headline

\[Treatment of nocturia in men with desmopressin\]. ([`pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5`](#source-pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5))

#### Summary

PubMed lists PMID 29492635 in Der Urologe. Ausg. A as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5`](#source-pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5))

#### Paragraph 1

PubMed lists PMID 29492635 in Der Urologe. Ausg. A as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5`](#source-pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5`](#source-pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5))

### Sources

<a id="source-pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5"></a>
- **\[Treatment of nocturia in men with desmopressin\]. · retained source version 1:2019-07-24:current:4f4f6b7946e551f72effbecc8da5e7ddbb18bce19167604393e64eab9ddaf86f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29492635/) (`pubmed-observation-pmid-29492635-2019-07-24-4f4f6b7946e5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Treatment of nocturia in men with desmopressin\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-29492635-desmopressin-v1 SHA-256: a24f19ebf50a7e374f21f98a393c70c30881addc95787ce0460efabe63315bd7.

---

<a id="pubmed-pmid-30216627-desmopressin-v1"></a>

## Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis.

> PubMed lists PMID 30216627 in BJU international as Journal Article, Review, Network Meta-Analysis, with publication-date metadata of 2018-10-31 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30216627-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-04-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30216627-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-30216627-desmopressin-v1
- Content SHA-256: `9e04cdf8539c68734f9160f9aae3cb7991d3e55c86a56a29c7201df3d00e5663`

### Claims and source pins

#### Headline

Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis. ([`pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc`](#source-pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc))

#### Summary

PubMed lists PMID 30216627 in BJU international as Journal Article, Review, Network Meta-Analysis, with publication-date metadata of 2018-10-31 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc`](#source-pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc))

#### Paragraph 1

PubMed lists PMID 30216627 in BJU international as Journal Article, Review, Network Meta-Analysis, with publication-date metadata of 2018-10-31 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc`](#source-pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc`](#source-pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc))

### Sources

<a id="source-pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc"></a>
- **Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis. · retained source version 1:2025-04-07:current:20a260df79bc1cbe3b5027f79eb3e37c6ce34592cae9cea90e89b8920110d3d0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30216627/) (`pubmed-observation-pmid-30216627-2025-04-07-20a260df79bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-30216627-desmopressin-v1 SHA-256: 9e04cdf8539c68734f9160f9aae3cb7991d3e55c86a56a29c7201df3d00e5663.

---

<a id="pubmed-pmid-30425276-desmopressin-v1"></a>

## Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis.

> PubMed lists PMID 30425276 in Scientific reports as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2018-11-13 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30425276-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-10-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30425276-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-30425276-desmopressin-v1
- Content SHA-256: `52d03e055dab5336607bc5ba5fe8b4a7a70d3b8c5ce4d2e1d0cc026981b48b09`

### Claims and source pins

#### Headline

Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis. ([`pubmed-observation-pmid-30425276-2023-10-04-545249053197`](#source-pubmed-observation-pmid-30425276-2023-10-04-545249053197))

#### Summary

PubMed lists PMID 30425276 in Scientific reports as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2018-11-13 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30425276-2023-10-04-545249053197`](#source-pubmed-observation-pmid-30425276-2023-10-04-545249053197))

#### Paragraph 1

PubMed lists PMID 30425276 in Scientific reports as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2018-11-13 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30425276-2023-10-04-545249053197`](#source-pubmed-observation-pmid-30425276-2023-10-04-545249053197))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30425276-2023-10-04-545249053197`](#source-pubmed-observation-pmid-30425276-2023-10-04-545249053197))

### Sources

<a id="source-pubmed-observation-pmid-30425276-2023-10-04-545249053197"></a>
- **Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis. · retained source version 1:2023-10-04:current:545249053197f145824070bbc1c797a48d7a5c0b3346792b8cda37c493d8e99c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30425276/) (`pubmed-observation-pmid-30425276-2023-10-04-545249053197`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-30425276-desmopressin-v1 SHA-256: 52d03e055dab5336607bc5ba5fe8b4a7a70d3b8c5ce4d2e1d0cc026981b48b09.

---

<a id="pubmed-pmid-30857487-desmopressin-v1"></a>

## Perioperative Desmopressin for Patients Undergoing Otolaryngologic Procedures: A Systematic Review.

> PubMed lists PMID 30857487 in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery as Journal Article, Systematic Review, with publication-date metadata of 2019-03-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30857487-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30857487-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-30857487-desmopressin-v1
- Content SHA-256: `b1f5610748a136013d39468d87dcb35ea53d12f61fa90d637951fcd21e212f6d`

### Claims and source pins

#### Headline

Perioperative Desmopressin for Patients Undergoing Otolaryngologic Procedures: A Systematic Review. ([`pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd`](#source-pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd))

#### Summary

PubMed lists PMID 30857487 in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery as Journal Article, Systematic Review, with publication-date metadata of 2019-03-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd`](#source-pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd))

#### Paragraph 1

PubMed lists PMID 30857487 in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery as Journal Article, Systematic Review, with publication-date metadata of 2019-03-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd`](#source-pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd`](#source-pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd))

### Sources

<a id="source-pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd"></a>
- **Perioperative Desmopressin for Patients Undergoing Otolaryngologic Procedures: A Systematic Review. · retained source version 1:2020-01-27:current:1a4a7f3f33cda4c91827e6fd1894b34168234d8308ef0347d77a7c9744f11f93** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30857487/) (`pubmed-observation-pmid-30857487-2020-01-27-1a4a7f3f33cd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Perioperative Desmopressin for Patients Undergoing Otolaryngologic Procedures: A Systematic Review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-30857487-desmopressin-v1 SHA-256: b1f5610748a136013d39468d87dcb35ea53d12f61fa90d637951fcd21e212f6d.

---

<a id="pubmed-pmid-31022158-desmopressin-v1"></a>

## Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria.

> PubMed lists PMID 31022158 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2019-03-25 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31022158-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31022158-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-31022158-desmopressin-v1
- Content SHA-256: `244657bf00806bc1e0b3e8b3bfc09f79c119b9597f0901aa5e714a36d1027ada`

### Claims and source pins

#### Headline

Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria. ([`pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf`](#source-pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf))

#### Summary

PubMed lists PMID 31022158 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2019-03-25 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf`](#source-pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf))

#### Paragraph 1

PubMed lists PMID 31022158 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2019-03-25 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf`](#source-pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf`](#source-pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf))

### Sources

<a id="source-pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf"></a>
- **Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria. · retained source version 1:2019-05-30:current:b37f0cd50acf41e8ac4bc89d46f8fe0a8ec258c4e438b26f19950677ea5b9609** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31022158/) (`pubmed-observation-pmid-31022158-2019-05-30-b37f0cd50acf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-31022158-desmopressin-v1 SHA-256: 244657bf00806bc1e0b3e8b3bfc09f79c119b9597f0901aa5e714a36d1027ada.

---

<a id="pubmed-pmid-32168509-desmopressin-v1"></a>

## Role of Desmopressin in the Critical Care Setting.

> PubMed lists PMID 32168509 in AACN advanced critical care as Journal Article, Review, with publication-date metadata of 2020-03-15 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32168509-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-12-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32168509-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-32168509-desmopressin-v1
- Content SHA-256: `76bb130a52415bbfc35198efd92ea5011be81a10dd1b1717e66a526051ea08df`

### Claims and source pins

#### Headline

Role of Desmopressin in the Critical Care Setting. ([`pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f`](#source-pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f))

#### Summary

PubMed lists PMID 32168509 in AACN advanced critical care as Journal Article, Review, with publication-date metadata of 2020-03-15 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f`](#source-pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f))

#### Paragraph 1

PubMed lists PMID 32168509 in AACN advanced critical care as Journal Article, Review, with publication-date metadata of 2020-03-15 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f`](#source-pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f`](#source-pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f))

### Sources

<a id="source-pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f"></a>
- **Role of Desmopressin in the Critical Care Setting. · retained source version 1:2020-12-21:current:97fe4f03461f4cf75bbddd96fc02df607a88d896c21c123ee986760971869d89** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32168509/) (`pubmed-observation-pmid-32168509-2020-12-21-97fe4f03461f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of Desmopressin in the Critical Care Setting." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-32168509-desmopressin-v1 SHA-256: 76bb130a52415bbfc35198efd92ea5011be81a10dd1b1717e66a526051ea08df.

---

<a id="pubmed-pmid-33552576-desmopressin-v1"></a>

## Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines.

> PubMed lists PMID 33552576 in Central European journal of urology as Journal Article, Review, with publication-date metadata of 2020-11-02 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33552576-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33552576-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-33552576-desmopressin-v1
- Content SHA-256: `c4e9afdc6d6917063403546683d3232abbdf258f0cfc2f4f8c9080bd3019bf4d`

### Claims and source pins

#### Headline

Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines. ([`pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18`](#source-pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18))

#### Summary

PubMed lists PMID 33552576 in Central European journal of urology as Journal Article, Review, with publication-date metadata of 2020-11-02 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18`](#source-pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18))

#### Paragraph 1

PubMed lists PMID 33552576 in Central European journal of urology as Journal Article, Review, with publication-date metadata of 2020-11-02 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18`](#source-pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18`](#source-pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18))

### Sources

<a id="source-pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18"></a>
- **Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines. · retained source version 1:2022-04-20:current:cce92b47eb18c4db29a4ec96e63540dc8da4f19a42e8bfdb8fa757a8db5c7751** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33552576/) (`pubmed-observation-pmid-33552576-2022-04-20-cce92b47eb18`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-33552576-desmopressin-v1 SHA-256: c4e9afdc6d6917063403546683d3232abbdf258f0cfc2f4f8c9080bd3019bf4d.

---

<a id="pubmed-pmid-35169370-desmopressin-v1"></a>

## Monosymptomatic Nocturnal Enuresis Treatment Using Alarm-Therapy and Desmopressin: A Meta-analysis Approach.

> PubMed lists PMID 35169370 in Medical archives (Sarajevo, Bosnia and Herzegovina) as Journal Article, Meta-Analysis, with publication-date metadata of 2021-12 (month precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35169370-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-05-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35169370-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35169370-desmopressin-v1
- Content SHA-256: `b6dafc4961ca0ac7bebf59464f4fdbb2801d5b6d61783b55695159e6654503b4`

### Claims and source pins

#### Headline

Monosymptomatic Nocturnal Enuresis Treatment Using Alarm-Therapy and Desmopressin: A Meta-analysis Approach. ([`pubmed-observation-pmid-35169370-2022-05-01-feccc6605836`](#source-pubmed-observation-pmid-35169370-2022-05-01-feccc6605836))

#### Summary

PubMed lists PMID 35169370 in Medical archives (Sarajevo, Bosnia and Herzegovina) as Journal Article, Meta-Analysis, with publication-date metadata of 2021-12 (month precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35169370-2022-05-01-feccc6605836`](#source-pubmed-observation-pmid-35169370-2022-05-01-feccc6605836))

#### Paragraph 1

PubMed lists PMID 35169370 in Medical archives (Sarajevo, Bosnia and Herzegovina) as Journal Article, Meta-Analysis, with publication-date metadata of 2021-12 (month precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35169370-2022-05-01-feccc6605836`](#source-pubmed-observation-pmid-35169370-2022-05-01-feccc6605836))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35169370-2022-05-01-feccc6605836`](#source-pubmed-observation-pmid-35169370-2022-05-01-feccc6605836))

### Sources

<a id="source-pubmed-observation-pmid-35169370-2022-05-01-feccc6605836"></a>
- **Monosymptomatic Nocturnal Enuresis Treatment Using Alarm-Therapy and Desmopressin: A Meta-analysis Approach. · retained source version 1:2022-05-01:current:feccc6605836efdf335711174228877beaf20ea7f66bbba7379b63551c0e3112** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35169370/) (`pubmed-observation-pmid-35169370-2022-05-01-feccc6605836`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Monosymptomatic Nocturnal Enuresis Treatment Using Alarm-Therapy and Desmopressin: A Meta-analysis Approach." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35169370-desmopressin-v1 SHA-256: b6dafc4961ca0ac7bebf59464f4fdbb2801d5b6d61783b55695159e6654503b4.

---

<a id="pubmed-pmid-35192687-desmopressin-v1"></a>

## Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis.

> PubMed lists PMID 35192687 in Blood advances as Journal Article, Meta-Analysis, Systematic Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35192687-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-11-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35192687-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35192687-desmopressin-v1
- Content SHA-256: `71d28a91405cb87f72ebdf877af5f2003c5a3582c9a9a0186ea6c874fa1201ed`

### Claims and source pins

#### Headline

Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. ([`pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70`](#source-pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70))

#### Summary

PubMed lists PMID 35192687 in Blood advances as Journal Article, Meta-Analysis, Systematic Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70`](#source-pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70))

#### Paragraph 1

PubMed lists PMID 35192687 in Blood advances as Journal Article, Meta-Analysis, Systematic Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70`](#source-pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70`](#source-pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70))

### Sources

<a id="source-pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70"></a>
- **Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. · retained source version 1:2022-11-05:current:2c7c65778b709c379cfd88a269bdd435ff528ab1af166c4cb6f4e2e6ce30abea** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35192687/) (`pubmed-observation-pmid-35192687-2022-11-05-2c7c65778b70`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35192687-desmopressin-v1 SHA-256: 71d28a91405cb87f72ebdf877af5f2003c5a3582c9a9a0186ea6c874fa1201ed.

---

<a id="pubmed-pmid-35199198-desmopressin-v1"></a>

## Desmopressin therapy in children and adults: pharmacological considerations and clinical implications.

> PubMed lists PMID 35199198 in European journal of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2022-02-23 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35199198-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35199198-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35199198-desmopressin-v1
- Content SHA-256: `c8207ef38addf40fa0c2b49d277cdbecb4ec5a8cdd3cecc5fc71d60992fa1eee`

### Claims and source pins

#### Headline

Desmopressin therapy in children and adults: pharmacological considerations and clinical implications. ([`pubmed-observation-pmid-35199198-2026-10-11-c62435664204`](#source-pubmed-observation-pmid-35199198-2026-10-11-c62435664204))

#### Summary

PubMed lists PMID 35199198 in European journal of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2022-02-23 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35199198-2026-10-11-c62435664204`](#source-pubmed-observation-pmid-35199198-2026-10-11-c62435664204))

#### Paragraph 1

PubMed lists PMID 35199198 in European journal of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2022-02-23 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35199198-2026-10-11-c62435664204`](#source-pubmed-observation-pmid-35199198-2026-10-11-c62435664204))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35199198-2026-10-11-c62435664204`](#source-pubmed-observation-pmid-35199198-2026-10-11-c62435664204))

### Sources

<a id="source-pubmed-observation-pmid-35199198-2026-10-11-c62435664204"></a>
- **Desmopressin therapy in children and adults: pharmacological considerations and clinical implications. · retained source version 1:2026-10-11:current:c62435664204d9869ec639d0835bf0d0119cbc9b5d95139a4d7226a84c088927** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35199198/) (`pubmed-observation-pmid-35199198-2026-10-11-c62435664204`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin therapy in children and adults: pharmacological considerations and clinical implications." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35199198-desmopressin-v1 SHA-256: c8207ef38addf40fa0c2b49d277cdbecb4ec5a8cdd3cecc5fc71d60992fa1eee.

---

<a id="pubmed-pmid-35478451-desmopressin-v1"></a>

## Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis.

> PubMed lists PMID 35478451 in Reviews in endocrine & metabolic disorders as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2022-04-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35478451-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35478451-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35478451-desmopressin-v1
- Content SHA-256: `ed9bbd6be1e3a1fe1db34727e07c45f71ef87bcb4dcabc3a52bf01e8bc5cc088`

### Claims and source pins

#### Headline

Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis. ([`pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7`](#source-pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7))

#### Summary

PubMed lists PMID 35478451 in Reviews in endocrine & metabolic disorders as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2022-04-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7`](#source-pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7))

#### Paragraph 1

PubMed lists PMID 35478451 in Reviews in endocrine & metabolic disorders as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2022-04-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7`](#source-pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7`](#source-pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7))

### Sources

<a id="source-pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7"></a>
- **Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis. · retained source version 1:2026-10-29:current:620564f0a8f7ad8eb591aa46475350866117e67efe85e37a4df1cacce2078af1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35478451/) (`pubmed-observation-pmid-35478451-2026-10-29-620564f0a8f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35478451-desmopressin-v1 SHA-256: ed9bbd6be1e3a1fe1db34727e07c45f71ef87bcb4dcabc3a52bf01e8bc5cc088.

---

<a id="pubmed-pmid-35839450-desmopressin-v1"></a>

## Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.

> PubMed lists PMID 35839450 in Blood as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-09-08 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35839450-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-02-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35839450-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35839450-desmopressin-v1
- Content SHA-256: `ce3915e44962b8d2c08946f41bfdf9b25a491d189714d60cba6cbba72a3a6d92`

### Claims and source pins

#### Headline

Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. ([`pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa`](#source-pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa))

#### Summary

PubMed lists PMID 35839450 in Blood as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-09-08 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa`](#source-pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa))

#### Paragraph 1

PubMed lists PMID 35839450 in Blood as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-09-08 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa`](#source-pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa`](#source-pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa))

### Sources

<a id="source-pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa"></a>
- **Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. · retained source version 1:2023-02-09:current:d46ad14e1aaacfd55a40724b7de9d92ab90604d2394f3262571e554d1ee73295** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35839450/) (`pubmed-observation-pmid-35839450-2023-02-09-d46ad14e1aaa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-35839450-desmopressin-v1 SHA-256: ce3915e44962b8d2c08946f41bfdf9b25a491d189714d60cba6cbba72a3a6d92.

---

<a id="pubmed-pmid-36656570-desmopressin-v1"></a>

## Desmopressin as a hemostatic and blood sparing agent in bleeding disorders.

> PubMed lists PMID 36656570 in European journal of haematology as Journal Article, Review, with publication-date metadata of 2023-02-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36656570-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-05-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36656570-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-36656570-desmopressin-v1
- Content SHA-256: `aac0bfe86ce589a60c5209e80f223bbe71576132f322e59b0d6f8b096781b0a2`

### Claims and source pins

#### Headline

Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. ([`pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7`](#source-pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7))

#### Summary

PubMed lists PMID 36656570 in European journal of haematology as Journal Article, Review, with publication-date metadata of 2023-02-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7`](#source-pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7))

#### Paragraph 1

PubMed lists PMID 36656570 in European journal of haematology as Journal Article, Review, with publication-date metadata of 2023-02-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7`](#source-pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7`](#source-pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7))

### Sources

<a id="source-pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7"></a>
- **Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. · retained source version 1:2024-05-02:current:ae31a1bf7eb72257b21e09603cd5e622dd343218a70ed4162cc3ea334c7b56ec** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36656570/) (`pubmed-observation-pmid-36656570-2024-05-02-ae31a1bf7eb7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin as a hemostatic and blood sparing agent in bleeding disorders." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-36656570-desmopressin-v1 SHA-256: aac0bfe86ce589a60c5209e80f223bbe71576132f322e59b0d6f8b096781b0a2.

---

<a id="pubmed-pmid-37041092-desmopressin-v1"></a>

## Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis.

> PubMed lists PMID 37041092 in Journal of pediatric surgery as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2023-03-17 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37041092-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-09-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37041092-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-37041092-desmopressin-v1
- Content SHA-256: `283eba62fcbac17a084f37e83cc3604b61a36d0f4f7aebd756976e3789a2144f`

### Claims and source pins

#### Headline

Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis. ([`pubmed-observation-pmid-37041092-2023-09-13-6c558221f541`](#source-pubmed-observation-pmid-37041092-2023-09-13-6c558221f541))

#### Summary

PubMed lists PMID 37041092 in Journal of pediatric surgery as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2023-03-17 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37041092-2023-09-13-6c558221f541`](#source-pubmed-observation-pmid-37041092-2023-09-13-6c558221f541))

#### Paragraph 1

PubMed lists PMID 37041092 in Journal of pediatric surgery as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2023-03-17 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37041092-2023-09-13-6c558221f541`](#source-pubmed-observation-pmid-37041092-2023-09-13-6c558221f541))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37041092-2023-09-13-6c558221f541`](#source-pubmed-observation-pmid-37041092-2023-09-13-6c558221f541))

### Sources

<a id="source-pubmed-observation-pmid-37041092-2023-09-13-6c558221f541"></a>
- **Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis. · retained source version 1:2023-09-13:current:6c558221f541d026bee079a05440a1a9aa2d400916ebfe8fc02f76205ecbe80c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37041092/) (`pubmed-observation-pmid-37041092-2023-09-13-6c558221f541`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-37041092-desmopressin-v1 SHA-256: 283eba62fcbac17a084f37e83cc3604b61a36d0f4f7aebd756976e3789a2144f.

---

<a id="pubmed-pmid-37649925-desmopressin-v1"></a>

## Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review.

> PubMed lists PMID 37649925 in Cureus as Journal Article, Review, with publication-date metadata of 2023-08-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37649925-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-09-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37649925-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-37649925-desmopressin-v1
- Content SHA-256: `587f2c05e5dc5531fee85e04de890f056f84e6dfee031ae72234b50912eb740e`

### Claims and source pins

#### Headline

Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review. ([`pubmed-observation-pmid-37649925-2023-09-01-135076512ed6`](#source-pubmed-observation-pmid-37649925-2023-09-01-135076512ed6))

#### Summary

PubMed lists PMID 37649925 in Cureus as Journal Article, Review, with publication-date metadata of 2023-08-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37649925-2023-09-01-135076512ed6`](#source-pubmed-observation-pmid-37649925-2023-09-01-135076512ed6))

#### Paragraph 1

PubMed lists PMID 37649925 in Cureus as Journal Article, Review, with publication-date metadata of 2023-08-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37649925-2023-09-01-135076512ed6`](#source-pubmed-observation-pmid-37649925-2023-09-01-135076512ed6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37649925-2023-09-01-135076512ed6`](#source-pubmed-observation-pmid-37649925-2023-09-01-135076512ed6))

### Sources

<a id="source-pubmed-observation-pmid-37649925-2023-09-01-135076512ed6"></a>
- **Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review. · retained source version 1:2023-09-01:current:135076512ed6341af4a502343710f94778f78661b1c3ab86d5b0a1849c3e9c52** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37649925/) (`pubmed-observation-pmid-37649925-2023-09-01-135076512ed6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-37649925-desmopressin-v1 SHA-256: 587f2c05e5dc5531fee85e04de890f056f84e6dfee031ae72234b50912eb740e.

---

<a id="pubmed-pmid-37928358-desmopressin-v1"></a>

## Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis.

> PubMed lists PMID 37928358 in Frontiers in pediatrics as Journal Article, Review, with publication-date metadata of 2023-10-19 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37928358-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-11-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37928358-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-37928358-desmopressin-v1
- Content SHA-256: `6ffd500256bbec82e4d034971b346cf91f6ea3473edc36216922afb9b082f746`

### Claims and source pins

#### Headline

Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis. ([`pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7`](#source-pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7))

#### Summary

PubMed lists PMID 37928358 in Frontiers in pediatrics as Journal Article, Review, with publication-date metadata of 2023-10-19 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7`](#source-pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7))

#### Paragraph 1

PubMed lists PMID 37928358 in Frontiers in pediatrics as Journal Article, Review, with publication-date metadata of 2023-10-19 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7`](#source-pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7`](#source-pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7))

### Sources

<a id="source-pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7"></a>
- **Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis. · retained source version 1:2023-11-07:current:131931d6e8b7ed8aa2b5253b8dd5e6ab9c43c935bab04c9b7a7c357fe7361881** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37928358/) (`pubmed-observation-pmid-37928358-2023-11-07-131931d6e8b7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-37928358-desmopressin-v1 SHA-256: 6ffd500256bbec82e4d034971b346cf91f6ea3473edc36216922afb9b082f746.

---

<a id="pubmed-pmid-40176766-desmopressin-v1"></a>

## Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A.

> PubMed lists PMID 40176766 in Haematologica as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-04-03 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40176766-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40176766-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-40176766-desmopressin-v1
- Content SHA-256: `38a4c431bb4f6a36a61098b93d78e8bf02b1539f0b4d08d2b361b892bf18f581`

### Claims and source pins

#### Headline

Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A. ([`pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7`](#source-pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7))

#### Summary

PubMed lists PMID 40176766 in Haematologica as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-04-03 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7`](#source-pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7))

#### Paragraph 1

PubMed lists PMID 40176766 in Haematologica as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-04-03 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7`](#source-pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7`](#source-pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7))

### Sources

<a id="source-pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7"></a>
- **Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A. · retained source version 1:2026-08-30:current:be0ac44ebeb754b461d4884953a111995fd1d900572c3d60dabd887e6a054cc0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40176766/) (`pubmed-observation-pmid-40176766-2026-08-30-be0ac44ebeb7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-40176766-desmopressin-v1 SHA-256: 38a4c431bb4f6a36a61098b93d78e8bf02b1539f0b4d08d2b361b892bf18f581.

---

<a id="pubmed-pmid-40728007-desmopressin-v1"></a>

## Desmopressin for nocturnal enuresis in children.

> PubMed lists PMID 40728007 in The Cochrane database of systematic reviews as Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40728007-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40728007-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-40728007-desmopressin-v1
- Content SHA-256: `f0ee7f950f71451bd6b4056b098381a68db7f3033524a29e74fb200acaef272a`

### Claims and source pins

#### Headline

Desmopressin for nocturnal enuresis in children. ([`pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664`](#source-pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664))

#### Summary

PubMed lists PMID 40728007 in The Cochrane database of systematic reviews as Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664`](#source-pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664))

#### Paragraph 1

PubMed lists PMID 40728007 in The Cochrane database of systematic reviews as Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664`](#source-pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664`](#source-pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664))

### Sources

<a id="source-pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664"></a>
- **Desmopressin for nocturnal enuresis in children. · retained source version 1:2026-09-24:current:35c7f8246664e6c9281a281334bf3928979027280901a1d08e46a7c4ae7e1bde** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40728007/) (`pubmed-observation-pmid-40728007-2026-09-24-35c7f8246664`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Desmopressin for nocturnal enuresis in children." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-40728007-desmopressin-v1 SHA-256: f0ee7f950f71451bd6b4056b098381a68db7f3033524a29e74fb200acaef272a.

---

<a id="pubmed-pmid-42864513-desmopressin-v1"></a>

## Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis.

> PubMed lists PMID 42864513 in Neurocritical care as Journal Article, Review, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42864513-desmopressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42864513-desmopressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-42864513-desmopressin-v1
- Content SHA-256: `69f7b84fadefd46baed251fa2f8f49e8cf3b262a6e6e5fd44144997fe62d92fb`

### Claims and source pins

#### Headline

Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis. ([`pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274`](#source-pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274))

#### Summary

PubMed lists PMID 42864513 in Neurocritical care as Journal Article, Review, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274`](#source-pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274))

#### Paragraph 1

PubMed lists PMID 42864513 in Neurocritical care as Journal Article, Review, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274`](#source-pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274`](#source-pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274))

### Sources

<a id="source-pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274"></a>
- **Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis. · retained source version 1:2026-10-12:current:063fcda0e2748010fa9a4c41166c13da6ac3be00ab934e687d80530a9e4e4278** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42864513/) (`pubmed-observation-pmid-42864513-2026-10-12-063fcda0e274`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/desmopressin.json#pubmed-pmid-42864513-desmopressin-v1 SHA-256: 69f7b84fadefd46baed251fa2f8f49e8cf3b262a6e6e5fd44144997fe62d92fb.

